

Washington University
Report on Federal Financial Assistance
Programs in Accordance with Uniform Guidance
For the Year Ended June 30, 2022
Employer Identification Number: 43-0653611

Washington University
Report on Federal Financial Assistance Programs in
Accordance with Uniform Guidance
Index
June 30, 2022

	Page(s)
A. FINANCIAL STATEMENTS AND SUPPLEMENTAL INFORMATION	
Report of Independent Auditors	1-3
Consolidated Financial Statements for the Years Ended June 30, 2022 and 2021.....	4-34
Schedule of Expenditures of Federal Awards	35-52
Notes to Schedule of Expenditures of Federal Awards	53
B. REPORTS ON COMPLIANCE AND ON INTERNAL CONTROLS	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards	54-55
Report of Independent Auditors on Compliance for Each Major Program and on Internal Control Over Compliance Required by Uniform Guidance	56-58
C. SCHEDULE OF FINDINGS AND QUESTIONED COSTS	
Part I – Summary of Auditors’ Results	59
Part II – Financial Statement Findings	60
Part III – Federal Award Findings and Questioned Costs	60
Corrective Action Plan	61
D. SUMMARY SCHEDULE OF PRIOR AUDIT FINDINGS	
Part IV – Summary Schedule of Prior Audit Findings and Status.....	62

Financial Statements and Supplemental Information



Report of Independent Auditors

To the Board of Trustees of Washington University:

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of Washington University and its subsidiaries (the “University”), which comprise the consolidated statements of financial position as of June 30, 2022 and 2021, and the related consolidated statements of activities and of cash flows for the years then ended, including the related notes (collectively referred to as the “consolidated financial statements”).

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the University as of June 30, 2022 and 2021, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors’ Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the University’s ability to continue as a going concern for one year after the date the financial statements are issued.

Auditors’ Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors’ report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS and *Government Auditing Standards*, will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that,



individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with US GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplemental Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended June 30, 2022 is presented for purposes of additional analysis as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated October 7, 2022 on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended June 30, 2022. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government*



Auditing Standards in considering the University's internal control over financial reporting and compliance.

PricewaterhouseCoopers LLP

St. Louis, Missouri
October 7, 2022

Washington University
Consolidated Statements of Financial Position
June 30, 2022 and 2021

(thousands of dollars)

	2022	2021
Assets		
Cash and cash equivalents	\$ 239,191	\$ 263,944
Investments	15,416,684	16,461,152
Accounts and notes receivable, net	709,568	646,996
Pledges receivable, net	423,296	407,232
Right-of-use assets	76,116	88,698
Other assets	329,870	327,370
Fixed assets, net	<u>3,242,141</u>	<u>3,017,355</u>
Total assets	<u>\$ 20,436,866</u>	<u>\$ 21,212,747</u>
Liabilities		
Accounts payable and accrued expenses	\$ 643,233	\$ 623,047
Deposits, advances and other	48,139	34,280
Lease liability	87,014	99,666
Professional liability	110,170	95,793
Deferred revenue and contract liabilities	130,480	161,045
Liabilities under split-interest agreements	35,873	40,883
Government supported student loans	12,902	17,550
Notes and bonds payable	<u>3,324,601</u>	<u>2,390,378</u>
Total liabilities	<u>4,392,412</u>	<u>3,462,642</u>
Net Assets		
Without donor restrictions	7,847,088	8,371,599
With donor restrictions	<u>8,197,366</u>	<u>9,378,506</u>
Total net assets	<u>16,044,454</u>	<u>17,750,105</u>
Total liabilities and net assets	<u>\$ 20,436,866</u>	<u>\$ 21,212,747</u>

The accompanying notes are an integral part of these consolidated financial statements.

Washington University
Consolidated Statements of Activities
Year Ended June 30, 2022

<i>(thousands of dollars)</i>	Without Donor Restrictions	With Donor Restrictions	Total
Revenues and other support			
Tuition and fees	\$ 513,132	\$	\$ 513,132
Endowment spending distribution	494,816	14,549	509,365
Investment income	10,145	385	10,530
Gifts	119,531	85,742	205,273
Grants and contracts revenues			
Direct costs recovered	579,308		579,308
Facilities and administrative costs recovered	222,969		222,969
Patient services, net	1,913,498		1,913,498
Auxiliary enterprises - sales and services	149,258		149,258
Educational activities - sales and services	187,342		187,342
Affiliated hospital revenues	109,789		109,789
Other revenue	35,078	11	35,089
Net assets released from restrictions	104,927	(104,927)	-
Total revenues and other support	<u>4,439,793</u>	<u>(4,240)</u>	<u>4,435,553</u>
Expenses:			
Compensation expense	2,506,855		2,506,855
Supplies, services, and other	1,278,017		1,278,017
Depreciation expense	218,070		218,070
Interest expense	74,887		74,887
Total expenses	<u>4,077,829</u>	<u>-</u>	<u>4,077,829</u>
Net operating results	<u>361,964</u>	<u>(4,240)</u>	<u>357,724</u>
Non-operating activities:			
Investment returns net of endowment spending	(895,974)	(1,282,659)	(2,178,633)
Permanently restricted gifts		102,269	102,269
Other non-operating	9,499	3,490	12,989
Non-operating, net	<u>(886,475)</u>	<u>(1,176,900)</u>	<u>(2,063,375)</u>
Change in net assets	(524,511)	(1,181,140)	(1,705,651)
Net Assets, Beginning of the Year	<u>8,371,599</u>	<u>9,378,506</u>	<u>17,750,105</u>
Net Assets, End of the Year	<u>\$ 7,847,088</u>	<u>\$ 8,197,366</u>	<u>\$ 16,044,454</u>

The accompanying notes are an integral part of these consolidated financial statements.

Washington University
Consolidated Statements of Activities
Year Ended June 30, 2021

<i>(thousands of dollars)</i>	Without Donor Restrictions	With Donor Restrictions	Total
Revenues and other support			
Tuition and fees	\$ 433,334	\$	\$ 433,334
Endowment spending distribution	354,542	11,237	365,779
Investment income	10,933	184	11,117
Gifts	76,625	81,829	158,454
Grants and contracts revenues			
Direct costs recovered	507,306		507,306
Facilities and administrative costs recovered	194,793		194,793
Patient services, net	1,667,815		1,667,815
Auxiliary enterprises - sales and services	90,249		90,249
Educational activities - sales and services	215,868		215,868
Affiliated hospital revenues	154,448		154,448
Other revenue	38,492	2	38,494
Net assets released from restrictions	107,829	(107,829)	-
Total revenues and other support	<u>3,852,234</u>	<u>(14,577)</u>	<u>3,837,657</u>
Expenses:			
Compensation expense	2,252,936		2,252,936
Supplies, services, and other	1,124,898		1,124,898
Depreciation expense	213,825		213,825
Interest expense	71,485		71,485
Total expenses	<u>3,663,144</u>	<u>-</u>	<u>3,663,144</u>
Net operating results	<u>189,090</u>	<u>(14,577)</u>	<u>174,513</u>
Non-operating activities:			
Investment returns net of endowment spending	2,323,518	3,417,121	5,740,639
Permanently restricted gifts		71,323	71,323
Other non-operating	(26,737)	22,062	(4,675)
Non-operating, net	<u>2,296,781</u>	<u>3,510,506</u>	<u>5,807,287</u>
Change in net assets	2,485,871	3,495,929	5,981,800
Net Assets, Beginning of the Year	<u>5,885,728</u>	<u>5,882,577</u>	<u>11,768,305</u>
Net Assets, End of the Year	<u>\$ 8,371,599</u>	<u>\$ 9,378,506</u>	<u>\$ 17,750,105</u>

The accompanying notes are an integral part of these consolidated financial statements.

Washington University
Consolidated Statements of Cash Flows
Years Ended June 30, 2022 and 2021

(thousands of dollars)

	2022	2021
Cash flows from operating activities		
Change in net assets	\$ (1,705,651)	\$ 5,981,800
Adjustments to reconcile change in net assets to cash provided by operating activities		
Realized and unrealized net losses and (gains) on investments	1,626,639	(6,177,960)
Depreciation expense	218,070	213,825
Permanently restricted gifts	(102,269)	(71,323)
Investments received as gifts - not permanently restricted	(18,540)	(12,173)
Proceeds from sales of investments received as gifts	18,540	12,173
Other non-cash adjustments	44,801	29,908
Changes in assets and liabilities		
Accounts and notes receivable, net	(126,160)	(67,005)
Pledges receivable, net	14,748	30,454
Accounts payable and accrued expenses	15,173	46,248
Deferred revenue and contract liabilities	(30,565)	2,229
Other assets and liabilities	18,301	(43,640)
Net cash used by operating activities	<u>(26,913)</u>	<u>(55,464)</u>
Cash flows from investing activities		
Proceeds from sales and maturities of investments	9,205,245	6,909,906
Purchases of investments	(9,748,041)	(6,612,196)
Purchases of fixed assets	(459,808)	(345,458)
Student loans disbursed	(14,053)	(14,376)
Student loan payments received	17,691	20,565
Net cash used in investing activities	<u>(998,966)</u>	<u>(41,559)</u>
Cash flows from financing activities		
Principal payments of debt	(66,598)	(185,011)
Proceeds from long-term debt issuance	1,005,877	159,486
Contributions restricted for long-term investment	40,924	65,002
Proceeds from sales of investments received as permanently restricted gifts	31,000	10,400
Other	(10,077)	(5,156)
Net cash provided by financing activities	<u>1,001,126</u>	<u>44,721</u>
Net decrease in cash	<u>(24,753)</u>	<u>(52,302)</u>
Cash and cash equivalents		
Beginning of year	263,944	316,246
End of year	<u>\$ 239,191</u>	<u>\$ 263,944</u>
Supplemental data		
Interest paid in cash	\$ 64,384	\$ 71,662
Noncash activities		
Contributions of securities and other noncash assets	49,540	23,103
Net change in accounts receivable for investments	58,440	(33,120)

The accompanying notes are an integral part of these consolidated financial statements.

Washington University

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

(All amounts in thousands of dollars)

1. Summary of Significant Accounting Policies

Organization

Washington University in St. Louis (the “university”), is an institution of higher education that, in furtherance of its role as a charitable and educational institution, engages in various activities, including instruction, research and provision of medical care.

Basis of Presentation and Use of Estimates

The consolidated financial statements have been prepared on the accrual basis of accounting. The consolidated financial statements are consolidated to include the accounts of the university and its affiliates. Significant consolidated affiliates include The Barnard Free Skin and Cancer Hospital, Parallel Properties LLC including its affiliates, Washington University Clinical Associates, LLC and associated physician practices, and Washington University Physicians in Illinois, Inc.

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Such estimates include, but are not limited to, the estimated useful lives of buildings and equipment, the fair value of certain investments (see footnote 2), the degree of precision in calculation of self-insurance reserves and adequacy of allowances for doubtful accounts. Actual results could differ from those estimates.

Net Assets

Resources are recorded based on the absence or existence of donor-imposed restrictions. Descriptions of the net asset categories are as follows:

- Net assets without donor restrictions are free of donor-imposed restrictions. Board-designated endowment funds are also included within net assets without donor restrictions.
- Net assets with donor restrictions represent net assets that consist of gifts and related earnings that are subject to donor-imposed restrictions or legal stipulations that have not yet been met by actions of the university and/or passage of time as well as gifts and trusts which, by donor restriction, are required to be held in perpetuity. Net assets required to be held in perpetuity at June 30, 2022 and 2021, are \$2,543,043 and \$2,442,688, respectively.

Revenues from sources other than contributions and investment returns are reported as increases in net assets without donor restrictions. Contributions are reported as increases in the appropriate category of net assets, except that contributions which impose donor restrictions that are met in the same fiscal year they are received are included in revenues without donor restrictions. Gains and investment income that are limited to specific uses by donor-imposed restrictions are reported as increases in net assets without donor restrictions if the restrictions are met in the same reporting period as the gains and income are recognized, except for gains and investment income earned by investment of donor-restricted

Washington University
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(All amounts in thousands of dollars)

endowments. Such amounts remain in net assets with donor restrictions until appropriated for expenditure. When a donor restriction expires due to the passage of time or the university's fulfillment of donor stipulated purpose, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the consolidated statements of activities as net assets released from restrictions. Donor restricted gifts that are to be held in perpetuity are reported in the non-operating section of the consolidated statements of activities. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as restricted support. Absent explicit donor stipulations about how long those long-lived assets must be maintained, the university reports expirations of donor restrictions when the donated or acquired long-lived assets are placed in service. Expenses are reported as decreases in net assets without donor restrictions.

The university's net assets as of June 30, 2022 consist of the following:

	Without donor restrictions	With donor restrictions	Total
Donor-restricted endowment funds	\$	\$ 7,116,348	\$ 7,116,348
Board-designated endowment funds	4,531,534	594,876	5,126,410
Investment in plant, net	843,517		843,517
Pledges		423,296	423,296
Other donor-restricted		62,846	62,846
Operating and other reserves	<u>2,472,037</u>		<u>2,472,037</u>
	<u>\$ 7,847,088</u>	<u>\$ 8,197,366</u>	<u>\$ 16,044,454</u>

The university's net assets as of June 30, 2021 consist of the following:

	Without donor restrictions	With donor restrictions	Total
Donor-restricted endowment funds	\$	\$ 8,268,427	\$ 8,268,427
Board-designated endowment funds	4,753,833	645,821	5,399,654
Investment in plant, net	790,380		790,380
Pledges		407,232	407,232
Other donor-restricted		57,026	57,026
Operating and other reserves	<u>2,827,386</u>		<u>2,827,386</u>
	<u>\$ 8,371,599</u>	<u>\$ 9,378,506</u>	<u>\$ 17,750,105</u>

Investments

Investment gains (losses) in excess of endowment spending distribution and the unrealized appreciation (depreciation) on investments are reported in the non-operating section of the consolidated statements of activities. Investments acquired by gift or bequest are initially recorded at market or appraised value at the date so acquired.

At June 30, 2022 and 2021, investments include \$925,978 and \$163,403, respectively, purchased with unexpended proceeds from the Series 2017 A Missouri Health and Educational

Washington University
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(All amounts in thousands of dollars)

Facilities Authority (MOHEFA) taxable revenue bonds issued July 6, 2017, the Series 2020A MOHEFA taxable revenue bonds issued April 3, 2020, and the Series 2022 taxable revenue bonds issued April 7, 2022. The 2017A and 2020A MOHEFA funds and the 2022 bond funds may be utilized for the purposes set forth in the relevant bond documents.

Fixed Assets

Fixed assets are stated at cost or at fair market values if received as a gift, less accumulated depreciation, computed on a straight-line basis over the estimated useful lives of the assets. Fixed assets include equipment and other assets acquired through sponsored programs during which title is retained by the resource provider. It is probable the university will be permitted to keep the assets when the program terminates. The cost and accumulated depreciation of fixed assets are removed from the records at the time of disposal. Fixed assets by classification at June 30, 2022 and 2021 consist of the following:

	<u>2022</u>	<u>2021</u>
Construction in progress	\$ 550,840	\$ 320,701
Land and improvements to land	206,433	190,825
Buildings	4,847,183	4,743,990
Equipment	<u>763,035</u>	<u>663,409</u>
Total cost	6,367,491	5,918,925
Accumulated depreciation	<u>(3,125,350)</u>	<u>(2,901,570)</u>
Total fixed assets, net	<u>\$ 3,242,141</u>	<u>\$ 3,017,355</u>

Collections

In addition to the Mildred Lane Kemper Art Museum, the university archives rare book collections, works of art, literary works, historical treasures and artifacts. These collections are protected and preserved for public exhibition, education, research and the furtherance of public service. They are neither disposed of for financial gain nor encumbered in any manner. Accordingly, such collections are not recognized or capitalized for financial statement purposes.

Leases

The university determines if an arrangement is or contains a lease at inception based on whether the contract conveys the right to control the use of identified property, plant, or equipment in exchange for consideration. The university has both leases under which it is obligated as a lessee and leases for which it is the lessor. Operating leases in which the university is a lessee are included in right-of-use (ROU) assets and lease liabilities on the consolidated statements of financial position. The university has elected the short-term lease exception under ASC 842 for all leases, and therefore, leases with an initial term of 12 months or less are not included on the consolidated statements of financial position. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease, measured on a discounted basis. The interest rate implicit in lease contracts is typically not readily determinable, and as such, the university uses its collateralized borrowing rate using a period comparable with the lease

Washington University

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

(All amounts in thousands of dollars)

term in determining the present value of lease payments. The lease term may, at the university's discretion, include options to extend or to terminate the lease that the university is reasonably certain to exercise. Lease expense for lease payments is recognized on a straight-line basis over the lease term within the supplies, services and other line of the consolidated statement of activities. Variable lease payments based on an index or rate, such as the consumer price index, are initially measured using the index or rate in effect at lease commencement. The university has lease agreements with non-lease components that relate to the lease components. The university elected the practical expedient to account for non-lease components and the lease components to which they relate as a single lease component for all leases. Leasing arrangements for which the university is the lessor are not material to the consolidated financial statements.

Financing Receivables

Financing receivables are principally loans made to students or their parents utilizing gifts, endowment payout, and university resources designated for that purpose and from funds provided by the United States government under the Federal Perkins Student Loan program. Loan funds are reported at estimated realizable value, as it is not practical to determine the fair value of loan fund receivables, which include a large component of federally sponsored student loans. Federally sponsored student loans have significant government restrictions as to marketability, interest rates, and repayment terms. Federal funds are ultimately refundable to the government and are recognized as a liability in the consolidated statements of financial position.

The university's loan portfolio includes over 4,800 individual loans and is geographically diverse. Loans are considered past due if the minimum payment is not received within thirty-one days past the due date. At June 30, 2022 and 2021, respectively 95% and 95% of the parent loans and 77% and 73% of the institutional student loans were considered current. Income earned on financing receivables is recorded on an accrual basis.

Deferred Revenue and Contract Liabilities

Deferred revenue is recognized on an accrual basis when payments for services are received in advance of performance by the university. The principle components of deferred revenue are clinical trial receipts, grants and contracts, and prepaid tuition and housing.

Tuition and Fees

Tuition and fee revenue, net of scholarships and other implicit price concessions, is recognized over-time using the output method of measuring progress in the fiscal year in which the educational programs are conducted. Students are invoiced at the commencement of each academic period. Payment is due when invoiced. The performance obligation, delivery of educational services, is satisfied as services are rendered. If delivery of the performance obligation is not complete as of fiscal year-end, a contractual liability is recorded. The deferred contract liability at June 30, 2022 and 2021 was \$50,249 and \$50,657, respectively, and is reported as deferred revenue and contract liabilities on the consolidated statement of financial position.

Demonstrated financial need is the major criteria for undergraduate students to receive financial aid. Graduate students often receive tuition support in connection with research assistant, teaching assistant and fellowship appointments. Total financial aid granted to

Washington University
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(All amounts in thousands of dollars)

students by the university, including aid provided to employees and their dependents, for the years ended June 30, 2022 and 2021, respectively, was \$458,928 and \$423,790.

The table below identifies student aid by type. Scholarships are reported net against tuition in the consolidated statements of activities. Other amounts are reported as expenses.

	2022	2021
Scholarships from unrestricted sources	\$ 246,375	\$ 227,169
Scholarship support from gifts, endowment and other restricted sources	<u>88,468</u>	<u>77,632</u>
Total scholarships	334,843	304,801
Employee and dependent tuition benefits	39,877	38,198
Stipends	82,732	79,221
Work study	<u>1,476</u>	<u>1,570</u>
Total	<u>\$ 458,928</u>	<u>\$ 423,790</u>

Gifts

Gifts, including unconditional promises to give, are recognized as revenues in the period the gift or promise is received. Gifts received for permanent endowments or perpetual trusts are reported as non-operating revenues. Gifts of assets other than cash are recorded at their estimated fair value at the date of gift and, unless instructed otherwise by the donor, are liquidated upon receipt or as soon as practical thereafter.

Conditional gifts and promises to give are not recognized until the conditions on which they depend are substantially met. Gifts, in the form of unconditional promises to give, to be received after one year are discounted at credit-adjusted tax exempt borrowing rates in accordance with fair value accounting. Pledges outstanding are discounted with rates ranging from 0.29% to 2.36%. Amortization of the discount is recorded as gift revenue. The university has received gifts which are recorded as gift revenue in the period the gift was made but are payable over a specified payment schedule of up to 10 years or more. During the gift payment term, the university is exposed to credit risk for the entity or individual that has made the gift. An allowance is made for uncollectible unconditional promises to give based upon management's judgment, past collections experience and other relevant factors.

Washington University
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(All amounts in thousands of dollars)

A summary of pledges receivable is as follows:

	<u>2022</u>	<u>2021</u>
In one year or less	\$ 182,711	\$ 152,990
Between two and five years	155,150	145,371
Over five years	<u>101,971</u>	<u>125,702</u>
	439,832	424,063
Less:		
Discount	(8,304)	(8,132)
Allowance for uncollectible amounts	<u>(8,232)</u>	<u>(8,699)</u>
Total	<u>\$ 423,296</u>	<u>\$ 407,232</u>

Grants and Contracts

The university receives grant and contract revenue from governmental and private sources. Revenue associated with the direct costs of sponsored programs is generally recognized as the related costs are incurred. At contract inception, the university determines whether the goods or services to be provided are to be accounted for as a single performance obligation or as multiple performance obligations. If multiple performance obligations are identified, the university generally uses the cost plus a margin approach to determine the relative standalone selling price of each performance obligation. Revenue from these contracts is earned over-time. Invoicing of the customer, if required, will generally be in accordance with terms of the contract with payment due when invoiced. Generally, the time between the receipt of payment and the transfer of goods and service under these contracts is less than one year.

The university records revenue without donor restrictions upon its recovery of direct and indirect costs applicable to those sponsored programs that provide for the full or partial reimbursement of such costs. Most grants awarded to the university by government agencies are conditional contributions. The principle condition attached to these awards is that the university must incur costs in accordance with the Office of Management and Budget's uniform guidance before costs can be reimbursed. Total amounts promised under these grants for which conditions have not yet been fulfilled are approximately \$1,086,536 and \$889,722 at June 30, 2022 and June 30, 2021, respectively. The recovery of indirect costs, also referred to as facilities and administrative costs is based on negotiated rates and represents recoveries of facilities and administrative costs incurred under grants and contracts agreements. Recovery of facilities and administrative costs of federally sponsored programs is at rates negotiated with the Department of Health and Human Services.

In some cases, the sponsor will prepay amounts in anticipation of costs to be incurred. In those cases, amounts received in excess of costs incurred are recorded as contract liabilities.

Patient Services Revenue

Net patient services revenue is reported at the amount that reflects the consideration to which the university expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payers (including health insurers and government programs),

Washington University

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

(All amounts in thousands of dollars)

and others. Generally, the university bills the patient and third-party payers several days after the services are performed. Revenue is recognized as performance obligations are satisfied.

Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected or actual charges which provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation.

Because the majority of its performance obligations relate to contracts with a duration of less than one year, the university has elected to apply the practical expedient provided in FASB ASC 606-10-50-14a, and therefore is not required to disclose the aggregate amounts of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period.

Generally patients who are covered by third-party payers are responsible for related deductibles and coinsurance, which vary in amount. The university also provides services to uninsured patients. The transaction price for both uninsured patients, as well as insured patients with deductibles and coinsurance, is estimated based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts and implicit price concessions. The university determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. The university determines its estimate of implicit price concessions based on historical collection experience with these classes of patients using a portfolio approach as a practical expedient. The portfolio approach is being used as there are a large volume of similar contracts with similar classes of customers. Management's judgment to group the contracts by portfolio is based on the payment behavior expected in each portfolio category. The effect of applying a portfolio approach to a group of contracts would not differ materially from considering each contract separately. Contractual adjustments to patient service revenue were \$2.35 billion and \$2.13 billion for the years ended June 30, 2022 and 2021, respectively.

The university has elected the practical expedient allowed under FASB ASC 606-10-32-18 and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. In certain instances, the university may enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract. The university reported net accounts receivable for patient services of \$179,019 and \$175,945, at June 30, 2022 and 2021, respectively.

Auxiliary Enterprises – Sales and Services

Auxiliary enterprises sales and services revenue is primarily earned over-time utilizing the output method of measuring progress. Auxiliary enterprise sales and services contracts will generally constitute a single performance obligation as there is a single promise. This revenue is composed primarily of on and off campus housing charges, dining services, and parking and transportation fees with separate contracts for each type of service. Housing, dining services and parking fees are invoiced to undergraduate students at the beginning of each academic period. Payment is due upon invoice issuance. Graduate students and undergraduates who

Washington University
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(All amounts in thousands of dollars)

live off campus sign rental agreements providing for monthly rent payments. Each contract for services in this category has a duration of one year or less. A contract liability is recorded for the delivery of performance obligations that is not completed prior to the fiscal year end.

Educational Activities – Sales and Services

Clinical trial revenue is earned over-time as the university provides services. The transaction price is negotiated with the customer and is usually based on standard rates for clinical services and the expected cost to complete the contract. Payment terms under these contracts vary but generally provide for the right to invoice the customer as work progresses, either based on units performed or the achievement of billing milestones. The university has determined that an input method using costs incurred as a basis to estimate revenue earned best depicts the pattern of transfer of control to the customer. In those limited cases where prepayments are significant, revenue is deferred until earned and a contract liability is recorded. The contract liabilities at June 30, 2022 and 2021 are not considered material and are reported as deferred revenue and contract liabilities on the consolidated statement of financial position.

Contracts in other educational sales and services cover a broad range of activities including physician services to affiliated and unaffiliated hospitals, executive education program fees and royalties. Revenue from the contracts in this category is earned over time as services are rendered. The measure of progress varies according to the nature of the services provided. Invoicing to customers is performed in the cadence required under the contracts and amounts invoiced generally are considered due upon receipt. Accruals for services provided but not yet invoiced are recorded at year end. Amounts receivable under service contracts are \$71,137 and \$64,239 at June 30, 2022 and 2021, respectively. Fees for executive education programs are often received in advance of the program and represent a contract liability. Such amounts are reported as deferred revenue and contract liabilities in the consolidated statement of financial position.

Affiliated Hospital Revenues

Affiliated hospital revenue is earned over-time as the various services are provided as an integrated performance obligation as more fully described in footnote 13. The measure of progress towards completion of those obligations is based on the day-to-day operations of the university's School of Medicine and the affiliated hospitals. Payments are received under the agreement semiannually. Amounts receivable under the agreement are \$39,202 and \$74,708 at June 30, 2022 and 2021 respectively.

Washington University

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

(All amounts in thousands of dollars)

Operating Results

The university's measure of operations as presented in the consolidated statements of activities includes income from tuition and fees, grants and contracts, medical services, contributions for operating programs, the endowment spending distribution and other revenues. Operating expenses are reported on the consolidated statements of activities as incurred for employee compensation, depreciation, interest and supplies, services and other. Operating results exclude investment gains (losses) except for the portion of gains utilized for the endowment spending distribution, contributions to be held in perpetuity, and other non-operating amounts.

Split-Interest Agreements

The university's split-interest agreements with donors consist primarily of charitable gift annuities and irrevocable charitable remainder trusts for which the university serves as trustee. Assets are invested and payments are made to donors and/or other beneficiaries in accordance with the respective agreements. Contribution revenues for charitable gift annuities and charitable remainder trusts are recognized after recording liabilities for the present value of the estimated future payments to be made to the respective donors and/or other beneficiaries. The discount rate used is a credit-adjusted rate in existence at the date of the gift. The rates used range from 0.67% to 2.25% for 2022 and 0.53% to 1.98% for fiscal year 2021. Annually, the university records the change in value of split-interest agreements by recording at fair value the assets that are associated with each trust and recalculating the liability for the present value of the estimated future payments to be made to the donors and/or other beneficiaries. For the years ending June 30, 2022 and 2021, the change in fair value was an increase of \$3,502 and \$1,661, respectively. As of June 30, 2022 and 2021, the university's liability under charitable gift annuities was \$17,141 and \$18,248, respectively.

Cash and Cash Equivalents

The university considers cash on hand and in banks and all highly liquid financial instruments with an original maturity of 90 days or less, except those amounts assigned to and invested by its investment managers, which amounts are classified as investments, to be cash and cash equivalents.

Income Taxes

The university is exempt from federal income taxes under Section 501 (c)(3) of the Internal Revenue Code except to the extent the university has unrelated business income, or consolidated for-profit affiliates incur taxes. There was no significant provision for income taxes in the current year. Management believes the university has no uncertain tax positions that result in material unrecognized tax expense/benefits.

2. Fair Value

The university follows FASB guidance for fair value measurements. This guidance defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

Washington University

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

(All amounts in thousands of dollars)

The FASB guidance establishes a hierarchy of valuation inputs based on the extent to which the inputs are observable in the marketplace. Observable inputs reflect market data obtained from sources independent of the university and unobservable inputs reflect the university's assumptions about how market participants would value an asset or liability based on the best information available. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value.

The following describes the hierarchy of inputs used to measure fair value and the primary valuation methodologies used by the university for financial instruments measured at fair value on a recurring basis. The three levels of inputs are as follows:

- Level 1 Quoted prices in active markets for identical assets or liabilities, such as exchange traded equity securities.
- Level 2 Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the same term of the assets or liabilities. Examples of Level 2 include U.S. Treasury securities and corporate bonds.
- Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The following table presents the financial instruments carried at fair value as of June 30, 2022, on the consolidated statements of financial position by caption and by the valuation hierarchy defined above. Amounts measured at net asset value are reported using the practical expedient under ASC topic 820 and excluded from the fair value hierarchy. Included as Level 2 fixed income are U.S. Treasury securities of approximately \$896,537.

Washington University
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(All amounts in thousands of dollars)

	Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Measured at Net Asset Value	Balance June 30, 2022
Investments					
Public equity					
Domestic	\$ 230,728		\$ 21,759	\$ 1,020,202	\$ 1,272,689
International	97,133			1,746,292	1,843,425
Fixed income - Nominal		1,256,010			1,256,010
Absolute return				667,558	667,558
Private capital			328,880	7,816,548	8,145,428
Short-term investments	219,104	4,408			223,512
Real assets	17,459		20,134	863,633	901,226
Other investments	962,546	3,663	60,141	32,119	1,058,469
Total investments at fair value	1,526,970	1,264,081	430,914	12,146,352	15,368,317
Investments not reported at fair value					
Affiliates - Equity basis					44,909
Accrued investment income					3,458
Total investments	\$ 1,526,970	\$ 1,264,081	\$ 430,914	\$ 12,146,352	\$ 15,416,684

The following table presents the financial instruments carried at fair value as of June 30, 2021, on the consolidated statements of financial position by caption and by the valuation hierarchy defined above. Amounts measured at net asset value are reported using the practical expedient under ASC topic 820 and excluded from the fair value hierarchy. Included as Level 2 fixed income are U.S. Treasury securities of approximately \$774,142.

	Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Measured at Net Asset Value	Balance June 30, 2021
Investments					
Public equity					
Domestic	\$ 290,611			\$ 1,625,359	\$ 1,915,970
International	61,800			2,948,440	3,010,240
Fixed income - Nominal		1,076,289			1,076,289
Absolute return				1,027,832	1,027,832
Private capital			254,301	7,741,398	7,995,699
Short-term investments	348,033	11,756			359,789
Real assets			749	715,436	716,185
Other investments	210,017	749	68,022	36,946	315,734
Total investments at fair value	910,461	1,088,794	323,072	14,095,411	16,417,738
Investments not reported at fair value					
Affiliates - Equity basis					40,876
Accrued investment income					2,538
Total investments	\$ 910,461	\$ 1,088,794	\$ 323,072	\$ 14,095,411	\$ 16,461,152

Beneficial interests in perpetual trusts held by third parties are valued at the present value of the future distributions expected to be received over the term of the agreement.

Washington University

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

(All amounts in thousands of dollars)

Following is a description of the university's valuation methodologies for assets and liabilities measured at fair value. The methods described below may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the university believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

Fair value for Level 1 is based upon quoted prices in active markets that the university has the ability to access for identical assets and liabilities. Market price data is generally obtained from exchange or dealer markets. The university does not adjust the quoted price for such assets and liabilities.

Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Inputs are obtained from various sources including market participants, dealers, and brokers.

Fair value for Level 3 is based on valuation techniques that use significant inputs that are unobservable as they trade infrequently or not at all. Trustees determine the valuation for beneficial interest trusts and split-interest agreements. Strategic real estate is valued at historical cost and is evaluated annually for impairment.

Investments measured at net asset value primarily consist of the university's ownership in alternative investments (principally limited partnership interests in absolute return, private capital investments, real assets, and other similar funds). The fair values (Net Asset Value ("NAV") or partner's capital per share) of the securities held by limited partnerships that do not have readily determinable fair values are determined by the respective general partners and are based on appraisals or other estimates that require varying degrees of judgment. If no public market exists for the investments, the fair value is determined by the general partners taking into consideration significant unobservable inputs including, among other things, the cost of the investments, prices of recent significant placements of investments of the same issuer, and subsequent developments concerning the companies to which the investments relate. Excluding the cost of the investment, significant increases or decreases in the remainder of those inputs could result in a significantly higher or lower fair value measurement. The university has performed due diligence with respect to these investments to ensure NAV or partner's capital per share is an appropriate measure of fair value as of June 30. NAVs are calculated by the investees in a manner consistent with generally accepted accounting principles for investment companies.

Significant terms of agreements with external investment managers or funds by major classes of investments are provided in the following tables.

Washington University
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(All amounts in thousands of dollars)

The following table summarizes the significant terms of the agreements with external investment managers or funds by major category at June 30, 2022:

Investments	Unfunded Commitment (1)	Remaining Life (2)	Redemption Terms	Redemption Restrictions
Public equities	\$	No Limit	Daily to annually, with same day-180 day notice	Lock-up provision periods range from none to 5 years. Certain investments include side pockets subject to external manager discretion.
Fixed income and short-term investments		No Limit	Daily, 1-2 days notice	No lock-up provision
Absolute return		No Limit	Quarterly to semi-annually with 45 – 180 days notice	Lock-up provision periods range from none to 3 years. Certain investments include side pockets subject to external manager's discretion.
Private capital	1,686,311	0 - 27 Years	Not eligible for redemption	Not redeemable
Real assets	397,436	0 - 11 Years	Not eligible for redemption	Not redeemable
Total	<u>\$ 2,083,747</u>			

Footnote (1): Includes \$15 million nonbinding unfunded commitments. The university is obligated under certain agreements to fund capital calls periodically up to specified commitment amounts. Such commitments are expected to be called over the life of the agreement and are not expected to be fully funded in the subsequent year.

Footnote (2): For private equities and real assets, assuming all extension options under the agreements are exercised and approved except for funds with no fund life end date or unlimited extension.

Washington University
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(All amounts in thousands of dollars)

The following table summarizes the significant terms of the agreements with external investment managers or funds by major category at June 30, 2021:

Investments	Unfunded Commitment (1)	Remaining Life (2)	Redemption Terms	Redemption Restrictions
Public equities	\$	No Limit	Daily to annually, with same day-180 day notice	Lock-up provision periods range from 0 to 5 years. Certain investments include side pockets subject to external manager discretion.
Fixed income and short-term investments		No Limit	Daily, 1-2 days notice	No lock-up provision periods
Absolute return		No Limit	Quarterly to semi-annually with 45 – 180 days notice	Lock-up provision periods range from 0 to 3 years. Certain investments include side pockets subject to external manager discretion.
Private capital	1,691,267	0 - 28 Years	Not eligible for redemption	Not redeemable
Real assets	337,723	0 - 11 Years	Not eligible for redemption	Not redeemable
Total	<u>\$ 2,028,990</u>			

Footnote (1): Includes \$21 million nonbinding unfunded commitments. The university is obligated under certain agreements to fund capital calls periodically up to specified commitment amounts. Such commitments are expected to be called over the life of the agreement and are not expected to be fully funded in the subsequent year.

Footnote (2): For private equities and real assets, assuming all extension options under the agreements are exercised and approved except for funds with no fund life end date or unlimited extension.

Public Equities

Public equities include investments in publicly-traded securities in domestic, developed international, emerging, and frontier markets. The majority of assets are held in pooled comingled funds which are valued at NAV as described above. Investments held in custody accounts are valued at quoted market price in accordance with Level 1 and Level 2 valuation techniques as described above.

Washington University
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(All amounts in thousands of dollars)

Fixed Income and Short-Term Investments

Investments in this class include domestic and international nominal fixed income instruments. Fixed income investments are held principally as liquid vehicles for operating needs and as a source of diversification. A significant component of non-endowment fixed income investments is held in highly liquid funds. The valuation of these funds is determined using a market approach in accordance with the techniques for Level 2 as described above.

Absolute Return

Investments in absolute return are typically held in commingled funds that employ various uncorrelated investment strategies including but not limited to equity hedged and event driven. These funds are valued at net asset value as described above.

Private Capital

Investments in private capital strategies are made in targeted categories including growth equity, venture capital, distressed credit, and corporate finance. The majority of these assets are in non-redeemable drawdown fund structures and distributions are received as underlying investments are liquidated. These funds are primarily valued at net asset value as described above.

Real Assets

Investments in the real assets class are made in targeted categories. The majority of these assets are held in non-redeemable drawdown fund structures that invest primarily in real estate and natural resources. These funds are primarily valued at net asset value as described above.

Level Three

The following tables roll forward the consolidated statement of financial position amounts for financial instruments classified by the university within Level 3 of the fair value hierarchy defined above for the years ended June 30, 2022 and 2021.

	Balance		Net Realized		Purchases, Sales		Transfers		Balance
	June 30, 2021		and Unrealized		and Settlements		in/(out) of		June 30, 2022
			Gains (Losses)		Net		Level 3, net		
Investments (by strategy)									
Private capital	\$ 254,301	\$	18,356	\$	56,223			\$	328,880
Real assets	749		(61)		19,446				20,134
Public equity			557				21,202		21,759
Other investments	68,022		(6,656)		(45)		(1,180)		60,141
Total	<u>\$ 323,072</u>	<u>\$</u>	<u>12,196</u>	<u>\$</u>	<u>75,624</u>	<u>\$</u>	<u>20,022</u>	<u>\$</u>	<u>430,914</u>

Washington University
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(All amounts in thousands of dollars)

	Balance June 30, 2020	Net Realized and Unrealized Gains (Losses)	Purchases, Sales and Settlements Net	Transfers in/(out) of Level 3, net	Balance June 30, 2021
Investments (by strategy)					
Private capital	\$ 158,996	\$ 246,611	\$ (202,365)	\$ 51,059	\$ 254,301
Real assets	2,128	101	(1,480)		749
Other investments	69,724	9,928	2,519	(14,149)	68,022
Total	<u>\$ 230,848</u>	<u>\$ 256,640</u>	<u>\$ (201,326)</u>	<u>\$ 36,910</u>	<u>\$ 323,072</u>

The amount of realized and unrealized gains (losses) for Level 3 investments for the period included in net assets attributable to the change in unrealized gains or losses relating to assets still held at June 30, 2022 and 2021 respectively, reported as investment returns net of endowment spending in the consolidated statements of activities by type of investment is:

	2022	2021
Private capital	\$ 18,587	\$ 43,818
Real assets	(959)	(823)
Public equity	557	
Other investments	(7,760)	8,023
Total	<u>\$ 10,425</u>	<u>\$ 51,018</u>

3. Investment Return

The following summarizes the return on investments. Investment income represents earnings on non-endowed funds. Return on investments is presented net of investment management fees. Certain investments, including some but not all of those in the absolute return and private capital categories, report investment returns net of fees.

	2022	2021
Investment income	\$ 10,530	\$ 11,117
Pooled endowment dividends and interest income, net of investment management fees	(42,629)	(71,542)
Pooled endowment distribution in excess of income	551,994	437,321
Pooled endowment spending distribution	509,365	365,779
Investment (losses) gains, net	(1,626,639)	6,177,960
Gains distributed as endowment distribution	(551,994)	(437,321)
Investment (losses) gains net of endowment spending distribution	(2,178,633)	5,740,639
Net investment return	<u>\$ (1,658,738)</u>	<u>\$ 6,117,535</u>

Washington University
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(All amounts in thousands of dollars)

4. Endowment

The state of Missouri has adopted legislation that incorporates the provisions outlined in the Uniform Prudent Management of Institutional Funds Act (UPMIFA). The statutory guidelines contained in this legislation relate to the prudent management, investment, and expenditure of donor-restricted endowment funds held by charitable organizations. Additionally, the legislation specifies factors for fiduciaries to consider prior to making a decision to appropriate from or accumulate into an institution's endowment funds.

At June 30, 2022, the university's endowment consists of 4,251 individual donor-restricted endowment funds and Board of Trustees or management-designated endowment funds for a variety of purposes plus split-interest agreements and other net assets where the assets have been designated for endowment. The net assets associated with endowment funds, including funds designated by the Board of Trustees or management to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

The university has interpreted Missouri UPMIFA as requiring the preservation of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, the university classifies as net assets with donor restrictions, (a) the original value of gifts donated to the donor-restricted endowment, (b) the original value of subsequent gifts to the donor-restricted endowment, (c) accumulations to the donor-restricted endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of donor-restricted endowment funds that are not restricted in perpetuity are considered restricted until the donor-imposed stipulations attached to those amounts have been met by actions of the university and/or passage of time and appropriated for expenditure in a manner consistent with the standard of prudence prescribed by UPMIFA.

Endowment net asset composition, which includes the effect of changes in endowment investments as well as other endowment-related assets and liabilities, by type of fund as of June 30, 2022:

	Without Donor Restriction	With Donor Restriction	Total
Donor-restricted endowment funds	\$	\$ 7,116,348	\$ 7,116,348
Board-designated endowment funds	4,531,534	594,876	5,126,410
Total endowment funds	<u>\$ 4,531,534</u>	<u>\$ 7,711,224</u>	<u>\$ 12,242,758</u>

Washington University
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(All amounts in thousands of dollars)

Changes in endowment net assets for the year ended June 30, 2022:

	Without Donor Restriction	With Donor Restriction	Total
Endowment net assets, beginning of year	\$ 4,753,833	\$ 8,914,248	\$ 13,668,081
Investment return			
Net investment income	(17,532)	(24,790)	(42,322)
Net decrease in investments (realized and unrealized)	(650,568)	(956,880)	(1,607,448)
Total investment return	(668,100)	(981,670)	(1,649,770)
Gifts	73	73,662	73,735
Appropriation of endowment assets for expenditure	(209,479)	(299,885)	(509,364)
Net transfers of funds	156,860	(2,234)	154,626
Allocation of endowment return to treasurer's investment pool	492,955	-	492,955
Other activity	5,392	7,103	12,495
Endowment net assets, end of year	\$ 4,531,534	\$ 7,711,224	\$ 12,242,758

Of the amount classified as endowment net assets with donor restrictions, \$5,072,881 represents the portion of endowment funds subject to time restrictions under Missouri's enacted version of UPMIFA.

Endowment net asset composition by type of fund as of June 30, 2021:

	Without Donor Restriction	With Donor Restriction	Total
Donor-restricted endowment funds	\$	\$ 8,268,427	\$ 8,268,427
Board-designated endowment funds	4,753,833	645,821	5,399,654
Total endowment funds	\$ 4,753,833	\$ 8,914,248	\$ 13,668,081

Washington University
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(All amounts in thousands of dollars)

Changes in endowment net assets for the year ended June 30, 2021:

	Without Donor Restriction	With Donor Restriction	Total
Endowment net assets, beginning of year	\$ 3,085,820	\$ 5,403,474	\$ 8,489,294
Investment return			
Net investment income	(29,528)	(40,961)	(70,489)
Net appreciation (realized and unrealized)	2,468,932	3,714,753	6,183,685
Total investment return	2,439,404	3,673,792	6,113,196
Gifts	109	78,578	78,687
Appropriation of endowment assets for expenditure	(150,971)	(214,808)	(365,779)
Net transfers of funds	29,884	2,797	32,681
Allocation of endowment return to treasurer's investment pool	(653,549)	(29,804)	(683,353)
Other activity	3,136	219	3,355
Endowment net assets, end of year	\$ 4,753,833	\$ 8,914,248	\$ 13,668,081

Of the amount classified as endowment net assets with donor restrictions, \$5,540,335 represents the portion of endowment funds subject to time restrictions under Missouri's enacted version of UPMIFA.

Endowment by Purpose

The purpose of endowment funds as of June 30, 2022:

	Without Donor Restriction	With Donor Restriction	Total
Restricted for general activities	\$ 2,976,006	\$ 5,122,820	\$ 8,098,826
Restricted for student assistance	1,237,317	1,583,362	2,820,679
Restricted for buildings and renovations	318,211	968,473	1,286,684
Life income		36,569	36,569
Total endowment net assets	\$ 4,531,534	\$ 7,711,224	\$ 12,242,758

The purpose of endowment funds as of June 30, 2021:

	Without Donor Restriction	With Donor Restriction	Total
Restricted for general activities	\$ 3,479,522	\$ 6,052,357	\$ 9,531,879
Restricted for student assistance	687,806	1,571,424	2,259,230
Restricted for buildings and renovations	586,505	1,244,725	1,831,230
Life income		45,742	45,742
Total endowment net assets	\$ 4,753,833	\$ 8,914,248	\$ 13,668,081

Washington University

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

(All amounts in thousands of dollars)

Endowment Funds with Deficits

As determined under UPMIFA, the fair value of assets associated with individual donor-restricted endowment funds may fall below the value of the initial and subsequent donor gift amounts (i.e., deficit). When donor endowment deficits exist, they remain classified as net assets with donor restrictions. Deficits of this nature were immaterial as of June 30, 2022 and 2021. The deficits resulted largely from unfavorable market fluctuations.

Return Objectives and Risk Parameters

The university has adopted endowment investment and spending policies that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of endowment assets. Under this policy, the return objective for the endowment assets, measured over a full market cycle, shall be to meet or exceed the return of its policy benchmark, based on the endowment's target allocation applied to the appropriate individual benchmarks. The university expects its endowment funds, over time, to provide an average rate of return that will exceed the sum of inflation and the spending rate. Actual returns in any given year may vary from this amount.

Strategies Employed for Achieving Investment Objectives

To achieve its long-term rate of return objectives, the university relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized gains) and current yield (interest and dividends). The university targets a diversified global asset allocation that places greater emphasis on equity-based and alternative investments to achieve its long-term objectives within prudent risk constraints.

Endowment Spending Allocation and Relationship of Spending Policy to Investment Objectives

The university has an endowment spending distribution policy designed to stabilize annual spending levels and preserve the real value of the endowment over time. Under this policy, earnings of the pooled endowment are distributed at a rate set annually to the schools and other units of the university. Consideration is given to the provisions of UPMIFA in determining the amount to appropriate. This spending rate must fall within the range of 3.0% to 5.5% of the five-year average market value of a unit of the pooled endowment. For 2022, the spending rate from the pooled endowment was 3.0% of the beginning market value of the pooled endowment. The spending rate is funded from current earnings and, in years when current earnings are insufficient, from previously accumulated earnings of the endowment.

Washington University
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(All amounts in thousands of dollars)

The university's endowment assets at June 30 are as follows:

	2022	2021
Pooled endowment and other funds	\$ 13,268,759	\$ 15,310,698
Life income trusts and pools	72,442	88,583
Externally administered trusts	31,655	37,338
Separately invested endowment	<u>7,904</u>	<u>9,674</u>
Total	13,380,760	15,446,293
Less: Operating funds invested in pool	<u>(1,098,702)</u>	<u>(1,780,908)</u>
Net endowment assets	<u>\$ 12,282,058</u>	<u>\$ 13,665,385</u>

The amounts above include term endowments of \$142,691 and \$150,012 as of June 30, 2022 and 2021, respectively.

5. Liquidity and Availability of Resources

At June 30, 2022 and 2021, the university's financial assets available for general expenditures within one year of the balance sheet date are as follows:

	2022	2021
Total assets at year end	\$ 20,436,866	\$ 21,212,747
Less:		
Accounts and notes receivable due in more than one year	(96,297)	(96,258)
Pledges receivable unavailable for general expenditure	(315,600)	(307,854)
Donor-restricted endowment funds	(7,279,612)	(8,283,442)
Board-designated endowment funds	(5,002,446)	(5,381,943)
Other long-term investments	(2,225,426)	(2,089,396)
Right-of-use assets	(76,116)	(88,698)
Other assets	(329,870)	(327,370)
Fixed assets	<u>(3,242,141)</u>	<u>(3,017,355)</u>
Total financial assets available within one year	<u>\$ 1,869,358</u>	<u>\$ 1,620,431</u>

The university's endowment funds consist of donor-restricted and board-designated endowment funds. As described in Note 4, the university has an endowment spending distribution policy with a spending rate range of 3.0% to 5.5% of the five-year average market value of a unit of the pooled endowment. For fiscal year 2023, the Board of Trustees approved a spending rate which will generate an endowment payout equaling or exceeding that of fiscal year 2022, including an allocation to the treasurer's investment pool, which will be available for operations during fiscal year 2023.

Washington University
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(All amounts in thousands of dollars)

In addition to these available financial assets, the university's annual expenditures will be primarily funded by current year operating revenues including tuition, patient services income, and sponsored research income. As part of the university's liquidity management, a policy is in place to structure its financial assets to be available as general expenditures, liabilities, and other obligations come due. The university also invests cash in excess of daily requirements in short-term investments. Furthermore, although the university does not intend to spend from its board-designated endowment funds other than amounts appropriated for general expenditure as part of its annual budget approval and appropriation process, amounts from its board-designated endowment that are free from investment restrictions could be made available if necessary. Other long-term investments are primarily composed of amounts designated by the university as reserves. Such investments are without donor restriction and could be drawn upon in the event of extreme stress. In the event of an unanticipated liquidity need, the university could also draw upon \$250,000 of available lines of credit at June 30, 2022.

6. Accounts and Notes Receivable

Accounts and notes receivable at June 30 were as follows:

	<u>2022</u>	<u>2021</u>
Patient services	\$ 486,749	\$ 489,726
Student and parent loans		
Parent loan fund	43,204	43,037
Government student loans	10,773	15,656
Institutional student loans	17,792	19,127
Due from affiliates	151,599	155,096
Sponsored project receivables	182,629	98,222
Other	<u>130,957</u>	<u>145,830</u>
	1,023,703	966,694
Less: Allowance for contractual adjustments and doubtful accounts	<u>(314,135)</u>	<u>(319,698)</u>
Total	<u>\$ 709,568</u>	<u>\$ 646,996</u>

Washington University

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

(All amounts in thousands of dollars)

7. Notes and Bonds Payable

Outstanding principal on bonds and notes payable at June 30, 2022 and 2021 consists of the following:

	Rates at June 30, 2022	Maturity	2022	2021
Missouri Health and Educational Facilities Authority				
\$88,000 of 2000B and C Series Variable Rate Bonds, due in full	0.01% - 0.65%	March 1, 2040	\$ 88,000	\$ 88,000
\$25,135 of 2003B Series Variable Rate Bonds, due in full	0.02% - 0.065%	February 15, 2033	25,135	25,135
\$77,495 of 2011C Series Revenue Bonds due serially from November 15, 2012 to November 15, 2037	.75% - 5.06%	November 15, 2037	47,215	49,595
\$200,785 of 2012A Series Revenue Bonds due serially from February 15, 2023 to February 15, 2047	2.39% - 3.69%	February 15, 2047	200,785	200,785
\$150,000 of 2014A Series Revenue Bonds due in full	4.07%	October 15, 2044	150,000	150,000
\$402,920 of 2016A Series Revenue Bonds due in full January 15, 2036 (\$109,300) and January 15, 2046 (\$293,620)	3.47% - 3.65%	January 15, 2036 and 2046	402,920	402,920
\$272,750 of 2016 B Series Revenue Bonds due in full	3.09%	September 15, 2051	272,750	272,750
\$375,000 of 2017 A Series Revenue Bonds, due in full	3.65%	August 15, 2057	375,000	375,000
\$450,000 of 2020 A Series Revenue Bonds, due in full	3.23%	May 15, 2050	450,000	450,000
\$1,000,000 of 2022 Series Revenue Bonds, due in full on April 15, 2054 and April 15, 2122	3.52% - 4.35%	April 15, 2054 and 2122	1,000,000	
Other Bonds:				
\$131,435 of 2015A Series Taxable Bonds due in full	3.79%	October 15, 2055	131,435	131,435
Other notes payable with various maturities			196,611	254,953
Total outstanding notes and bonds payable			3,339,851	2,400,573
Unamortized original issue premiums/discounts and cost of issuance, net			(15,250)	(10,195)
Total			<u>\$ 3,324,601</u>	<u>\$ 2,390,378</u>

Bonds payable are redeemable at the option of the university at various times from 2022 through 2122. The university is required to maintain certain ratios and comply with other restrictive covenants principally that the university maintains a ratio of expendable financial resource to bonds and notes payable of at least 1.25 times. The university is in compliance with this covenant. During 2022 and 2021, interest, accretion of debt discount and related fees incurred on notes and bonds payable totaled \$84,511 and \$75,531, respectively.

Washington University
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(All amounts in thousands of dollars)

Maturities on notes and bonds payable for the next five fiscal years are as follows:

2023	\$	79,942
2024		2,577
2025		2,627
2026		134,837
2027		32,522
Thereafter		3,087,346

During fiscal 2022, the university issued \$1,000,000 of Series 2022 taxable revenue bonds for the purpose of providing funds for general needs in keeping with the charitable mission of the university. The bonds bear a fixed rate of 3.52% to 4.35% and will mature on April 15, 2054 and 2122. During fiscal 2021, the university borrowed \$132,400 under a five year term note, the proceeds of which were used to retire the balance of the 1996 MOHEFA bonds.

The university has other lines of credit, which generally expire annually, aggregating \$332,720, of which \$269,146 is available at June 30, 2022. The university expects that these lines of credit will be renewed but can make no assurances.

8. Operating Leases

The university and its consolidated affiliates primarily lease laboratories, office space, and medical offices for educational, research, and patient care purposes under operating leases expiring through fiscal 2032. At June 30, 2022 and 2021, the weighted average remaining lease term was 6.0 and 6.5 years and the weighted average discount rate was 3.05% and 3.05%, respectively. Lease expense is included in supplies, services, and other on the consolidated statement of activities.

The undiscounted cash flows due by fiscal year related to significant non-cancelable operating leases with initial terms in excess of one year as of June 30, 2022, along with a reconciliation to the discounted amount recorded as of June 30, 2022 were as follows:

2023	\$	23,450
2024		18,546
2025		15,106
2026		14,073
2027		11,373
Thereafter		19,920
Total minimum lease payments	\$	102,468
Less: Imputed interest		(15,454)
Total lease liabilities	\$	87,014

Washington University
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(All amounts in thousands of dollars)

9. Derivative and Other Financial Instruments

The university utilizes derivative instruments including futures, swaps, and options, to manage market risk, to provide temporary investment exposure in stocks and bonds, and to manage currency and interest rate exposures. When directly implementing a derivative strategy, the university uses a third party manager to execute, settle and manage the positions on a non-discretionary basis. These contracts are valued at periodic intervals such as daily, monthly, and quarterly as well as at June 30, with the resulting changes in the values of the contracts either added to or deducted from the university's custodial account. Gains or losses from these derivative instruments are reported as realized and unrealized gains or losses in the consolidated statements of activities. Indirect strategies in derivatives held by limited partnerships and commingled investment trusts in which the university invests pose no off-balance sheet risk to the university due to the limited liability structure of the investments. Derivatives are also used to manage operating expenses but are not material to the consolidated financial statements. No derivative contracts are designated as hedges for accounting purposes.

10. Functional Expenses

Operating expenses are reported on the consolidated statements of activities in natural categories. Expenses reported by functional categories include allocations of costs for operation and maintenance of plant, interest on indebtedness and depreciation expense. Operation and maintenance of plant and depreciation are allocated to functional categories largely based on square footage. Interest expense is allocated based on specific identification of the uses of debt proceeds. Instruction expenses include instruction, departmental research and patient care costs.

Operating expenses by functional and natural classification for the year ended June 30, 2022 are as follows:

	Compensation and benefits	Supplies, services and other	Depreciation	Interest	Total
Instruction	\$ 1,540,577	\$ 853,231	\$ 81,293	\$ 22,521	\$ 2,497,621
Research	400,359	236,454	53,147	12,692	702,652
Academic Support	317,319	36,562	34,553	11,443	399,877
Student Services	58,693	47,722	2,373	911	109,699
Institutional Support	145,668	35,268	6,541	691	188,168
Auxiliary Enterprises	18,121	53,117	37,904	26,481	135,624
Other	26,118	15,663	2,260	147	44,188
Total	<u>\$ 2,506,855</u>	<u>\$ 1,278,017</u>	<u>\$ 218,070</u>	<u>\$ 74,887</u>	<u>\$ 4,077,829</u>

Washington University
Notes to Consolidated Financial Statements
June 30, 2022 and 2021

(All amounts in thousands of dollars)

Operating expenses by functional and natural classification for the year ended June 30, 2021 are as follows:

	Compensation and benefits	Supplies, services and other	Depreciation	Interest	Total
Instruction	\$ 1,489,996	\$ 814,548	\$ 75,136	\$ 18,189	\$ 2,397,869
Research	375,891	168,192	54,943	13,278	612,304
Academic Support	176,099		32,063	10,354	218,516
Student Services	43,105	45,323	5,318	2,443	96,189
Institutional Support	124,096	25,399	4,538	799	154,832
Auxiliary Enterprises	19,745	60,265	39,749	26,263	146,022
Other	24,004	11,171	2,078	159	37,412
Total	<u>\$ 2,252,936</u>	<u>\$ 1,124,898</u>	<u>\$ 213,825</u>	<u>\$ 71,485</u>	<u>\$ 3,663,144</u>

11. Commitments and Contingencies

At June 30, 2022 and 2021, the university had outstanding commitments under certain construction contracts in the amount of \$507,830 and \$262,844, respectively.

The university maintains a self-insurance program for professional liability at the Medical School and a separate program for Washington University Physicians in Illinois. This program is supplemented with commercial excess insurance above the university's self-insurance retention. Funding for the program reserves is based on claims made. The assets supporting the funded reserve are reported as investments in the consolidated statements of financial position. The university also accrues for an estimate of claims incurred but not reported. Reserves, funded and unfunded, are based upon actuarial studies and represent undiscounted estimated claims and related costs. The total self-insurance reserves at June 30, 2022 and 2021, respectively, were \$110,170 and \$95,793. Self-insurance reserves are necessarily estimates based on historical loss experience and other factors, and while management believes that the reserves are adequate, the ultimate liabilities may be in excess of or less than the amounts provided.

The university is a party, along with other universities, to an agreement with a reciprocal risk retention group for purposes of obtaining general liability and auto liability insurance coverage in excess of a pre-determined retention level. Under the terms of these agreements, the university can be called upon to make additional capital contributions. In management's view, any such capital calls would not be material.

The university is involved in various legal proceedings arising in the normal course of operations. Although the outcome of any legal proceeding cannot be predicted with certainty, it is the opinion of the university's management that the outcome of these proceedings individually or in the aggregate, will not have a material adverse effect on the business, consolidated statements of activities, financial position or liquidity of the university.

Washington University

Notes to Consolidated Financial Statements

June 30, 2022 and 2021

(All amounts in thousands of dollars)

12. Retirement Plan

The university provides its faculty and staff with a defined contribution (403(b)) retirement savings plan in which employee contributions, university contributions and investment earnings accumulate to assist employees at retirement. Participating employees own individual retirement accounts through the Teachers Insurance and Annuity Association (TIAA) and College Retirement Equity Fund (CREF). Under this arrangement, the university and plan participants make monthly contributions to TIAA-CREF. The amount of contribution made by the university is based on employee's hire date and/or age. Vesting provisions are full and immediate. The university's share of the cost of these benefits in 2022 and 2021 was \$117,581 and \$71,490, respectively. The university provides dependent tuition benefits to qualified retirees. The liability under this plan was \$15,807 and \$18,917 as of June 30, 2022 and 2021, respectively.

13. Agreements with Affiliated Hospitals

The university has an affiliation agreement with BJC in relation to Barnes Jewish Hospital (BJH), St. Louis Children's Hospital (SLCH), and Barnes Jewish West County Hospital (BJWCH), collectively the Hospitals, which expire December 31, 2027, but may be canceled upon a one-year written notice by either party. This agreement relates to various operating activities of the Hospitals including Orthopedic Center (OC) in Chesterfield, Siteman Cancer Center – South County, Center for Advanced Medicine (CAM) in South County, BJH Psychiatric Support Center (PSC), Children's Specialty Care Center in Town and Country, and Children's Specialty Care Center in South County.

Under the terms of the affiliation agreement, the university trains and supervises medical residents and interns and manages certain clinical and research activities of the Hospitals. The Hospitals compensate the university for services provided through a fixed annual base payment (adjusted annually for inflation) plus an additional variable payment based on the combined net operating income of the Hospitals. In addition, the university derives revenue from patient services provided at Barnes-Jewish at St. Peters Hospital under an agreement with that hospital and BJH. Payments to the university under affiliation agreements are reported as affiliated hospital revenue on the consolidated statements of activities (see footnote 1). During 2013, BJH agreed to fund on a cost-reimbursement basis over a period of years, certain expenditures by the university. Payments of \$56,235 and \$17,923 were received or accrued as gifts on the consolidated statements of activities under the agreement during 2022 and 2021, respectively.

14. Subsequent Events

The university has performed an evaluation of subsequent events through October 7, 2022, which is the date the consolidated financial statements were issued.

Supplemental Information

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2022

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Research and Development Cluster					
DEPARTMENT OF DEFENSE					
Advanced Research Projects Agency					
Research and Technology Development	12.910	Columbia University	HR00112220022/1(GG018225-01)	\$ 18,205	\$ -
Research and Technology Development	12.910	Vanderbilt University Medical Center	HR00111820001	295,652	-
Defense Advanced Research Projects Agency					
Defense Advanced Research Projects Agency	12.RD	Charles River Analytics Inc	N6600121C4013	508,601	-
Defense Advanced Research Projects Agency	12.RD	Raytheon BBN Technologies Corp.	FA875019C0056	136,326	-
Defense Advanced Research Projects Agency	12.RD	Two Six Labs, LLC	HR00117C0111	343,362	-
Defense Threat Reduction Agency					
Basic Scientific Research - Combating Weapons of Mass Destruction	12.351			452,033	326,864
Department of Defense					
Department of Defense	12.RD	Advanced Cooling Technologies	N6833521C0432	41,989	-
Department of Defense	12.RD	Cepheid Inc.	W15QKN-16-9-1002	37,715	-
Department of Defense	12.RD	Eccalon LLC	47QTCa18DooDK	326,363	-
Department of Defense	12.RD	North Carolina State University	H9823019Doo12/0002	190,374	-
Department of the Air Force, Material Command					
Air Force Defense Research Sciences Program	12.800			455,571	-
Air Force Defense Research Sciences Program	12.RD			(2,277)	-
Air Force Defense Research Sciences Program	12.800	Nanosonic	FA864920P0983	361,633	-
Air Force Defense Research Sciences Program	12.800	Pennsylvania State University	FA95502110202	359,389	-
Air Force Defense Research Sciences Program	12.800	Princeton University	FA95502010241	96,396	-
Air Force Defense Research Sciences Program	12.800	Vanderbilt University	FA95501810126		-
Department of the Navy, Office of the Chief of Naval Research					
Applied Research and Exploratory Development	12.RD	Indiana University-Purdue University Indianapolis	N000142112630	101,661	-
Applied Research and Exploratory Development	12.RD	University Of Southern California	N000141812632	56,234	-
Basic and Applied Scientific Research	12.300			1,016,824	48,354
Basic and Applied Scientific Research	12.300	University of California, Davis	N000141712961	330,282	-
Office of the Secretary of Defense					
Basic, Applied, and Advanced Research in Science and Engineering	12.630	Advanced Regenerative Manufacturing Institute	F0017/W911NF173003	831,758	-
Basic, Applied, and Advanced Research in Science and Engineering	12.630	Battelle Memorial Institute	W911SR-15-2-0001	6,899	-
Basic, Applied, and Advanced Research in Science and Engineering	12.630	University Of Iowa	FA95502010346	12,854	-
U.S. Army Material Command					
Basic Scientific Research	12.431			1,101,000	52,878
Basic Scientific Research	12.431	Georgia Institute of Technology	W911W6212001	18,513	-
Basic Scientific Research	12.431	Leonard Wood Institute	W911NF420034	581	-
Basic Scientific Research	12.431	University of Michigan	W911NF1810208	87,339	-
Basic Scientific Research	12.431	University of Minnesota	W911NF1810240	183,697	-
Basic Scientific Research	12.431	University of Southern California	W911NF2110327	164,907	-
Basic Scientific Research	12.431	Virginia Tech	W911NF2010141	26,998	-
U.S. Army Medical Command					
Military Medical Research and Development	12.RD			4,911,678	1,317,309
Military Medical Research and Development	12.420			12,762,284	576,506
Military Medical Research and Development	12.420	Children's Hospital Corporation	W81XWH1710532	12,741	-
Military Medical Research and Development	12.420	Cornell University	W81XWH1810667	86,509	-
Military Medical Research and Development	12.420	Health Research Inc	W81XWH1910674	484	-
Military Medical Research and Development	12.420	IDBiologics Inc	W81XWH1910405	48,171	-
Military Medical Research and Development	12.420	Johns Hopkins University	X81XWH1620060	244	-
Military Medical Research and Development	12.420	Saint Louis University	W81XWH12010241	100,915	-
Military Medical Research and Development	12.420	SARC	W81XWH1710695	33,140	-
Military Medical Research and Development	12.420	The Brigham And Women's Hospital Inc	W81XWH1510269	25,580	-
Military Medical Research and Development	12.420	University of Alabama Birmingham	W81XWH1-17-2-0037	(1,064)	-
Military Medical Research and Development	12.420	University of Colorado Denver	W81XWH1510504	32,347	-
Military Medical Research and Development	12.420	University of Maryland	W81XWH1710668	4,399	-
Military Medical Research and Development	12.420	University of Missouri System	W81XWH12110173	35,043	-
Military Medical Research and Development	12.420	University of North Carolina Chapel Hill	W81XWH1910117	8,285	-
Military Medical Research and Development	12.420	University Of South Carolina	W81XWH1920051	29,926	-
Military Medical Research and Development	12.420	Veterans Research & Education Foundation of St. Louis	W81XWH1810548	133,375	-
Military Medical Research and Development	12.420	Veterans Research & Education Foundation of St. Louis	W81XWH2010785	81,592	-
TOTAL DEPARTMENT OF DEFENSE				25,866,528	2,321,911
DEPARTMENT OF EDUCATION					
Office of Postsecondary Education					
Graduate Assistance in Areas of National Need	84.200			6,414	-
Office of Special Education and Rehabilitative Services					
Special Education - Personnel Development to Improve Services and Results for Children with Disabilities	84.325			407,954	-
TOTAL DEPARTMENT OF EDUCATION				414,368	-
DEPARTMENT OF ENERGY					
Department of Energy					
Office of Science Financial Assistance Program	81.049			3,698,117	603,791
Office of Science Financial Assistance Program	81.049	Aerosol Dynamics	DESC0020495	4,373	-
Office of Science Financial Assistance Program	81.049	Georgia Tech	DE-SC0012577	156,899	-
Office of Science Financial Assistance Program	81.049	Michigan State University	DE-SC0013617	150,159	-
Office of Science Financial Assistance Program	81.049	TDA Research, Inc	DESC0018502	20,991	-
Office of Science Financial Assistance Program	81.049	University of Wisconsin	DE-SC0021985	7,870	-
Renewable Energy Research and Development	81.087			58,615	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2022

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Fossil Energy Research and Development	81.089			2,004,109	373,198
Fossil Energy Research and Development	81.089	Texas A&M University	M2200657	60,314	-
Stewardship Science Grant Program	81.112			253,210	-
Stewardship Science Grant Program	81.112	Krell Institute	DENA0003960	31,667	-
Stewardship Science Grant Program	81.112	Texas A&M University	DENA0003841	112,140	-
Advanced Research Projects Agency - Energy	81.135			375,911	-
Department of Energy	81.RD	Battelle Memorial Institute	394636	7,023	-
Department of Energy	81.RD	Battelle Memorial Institute	587759	9,462	-
Department of Energy	81.RD	Fermi National Accelerator Lab	DEAC0207CH11359	77,243	-
Department of Energy	81.RD	Lawrence Livermore National Laboratory	DEAC5207NA27344	58,227	-
Department of Energy	81.RD	Sandia National Laboratory	1888542	25,117	-
Department of Energy	81.RD	TRIAD National Security, Los Alamos National Laboratory	89233218CNA000001	30,249	-
Department of Energy	81.RD	University of California, Lawrence Berkley National Laboratory	DEAC0205CH11231	115,536	-
TOTAL DEPARTMENT OF ENERGY				7,257,232	976,989
DEPARTMENT OF HEALTH AND HUMAN SERVICES					
Administration for Children and Families					
Administration for Children and Families	93.RD	Vision for Children	FACTSTL	111,192	-
Administration for Community Living					
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93-433			356,891	44,852
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93-433	University of Wisconsin, Milwaukee	901FDV0006	2,753	-
ACL Assistive Technology State Grants for Protection and Advocacy	93-843	Tulane University	5R01HL12242607	67,830	-
Agency for Healthcare Research and Quality					
Research on Healthcare Costs, Quality and Outcomes	93-226			1,701,188	282,889
Research on Healthcare Costs, Quality and Outcomes	93-226	Children's Hospital of Philadelphia	5R01HS027428	50,560	-
COVID19-Research on Healthcare Costs, Quality and Outcomes	93-226	Columbia University	1R01HS02845401A1	7,032	-
Research on Healthcare Costs, Quality and Outcomes	93-226	University Of Chicago	1R01HS02780401A1	29,376	-
Research on Healthcare Costs, Quality and Outcomes	93-226	University of Iowa	5R01HS02672404	108,625	-
Research on Healthcare Costs, Quality and Outcomes	93-226	University of Maryland, Baltimore	5R01HS02545604	29,961	-
COVID19-Research on Healthcare Costs, Quality and Outcomes	93.RD	University of New Mexico	75Q80120C00003	68,893	-
Centers for Disease Control					
Birth Defects and Developmental Disabilities, Prevention, and Surveillance	93-073			136,289	-
Birth Defects and Developmental Disabilities, Prevention, and Surveillance	93-073	Johns Hopkins University	5U01DD00129702	3,176	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93-084			1,013,205	-
Prevention of Disease, Disability, and Death by Infectious Diseases	93-084	North Carolina State University	1U01CK0005870100	216,895	-
COVID19-Prevention of Disease, Disability, and Death by Infectious Diseases	93-084	North Carolina State University	1U01CK00058703	174,216	-
Centers for Research and Demonstration for Health Promotion and Disease Prevention	93-135			1,044,025	-
Injury Prevention and Control Research and State and Community Based programs	93-136			131,375	30,193
COVID19-Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects	93-185	University of Florida	1NU21P0005970100	121,736	64,537
Occupational Safety and Health Program	93-262			380,692	242,603
Occupational Safety and Health Program	93-262	Center For Construction Research & Training	1U60OH009762	198,065	-
Occupational Safety and Health Program	93-262	Center For Construction Research & Training	1U60OH00976211	187,243	-
Occupational Safety and Health Program	93-262	University of California	5R01OH01166103	148,718	-
Occupational Safety and Health Program	93-262	University of Colorado	6U19OH0112270501	554	-
Occupational Safety and Health Program	93-262	University of Iowa	6U19OH008868-16-02	30,726	-
Occupational Safety and Health Program	93-262	University of Iowa	1U19OH00886801	65,568	-
Occupational Safety and Health Program	93-262	University of Iowa	5U19OH00886815	65,199	-
Centers for Disease Control and Prevention, Investigations and Technical Assistance	93-283			304,755	160,802
Early Hearing Detection and Intervention Information System Surveillance Program	93-314	University of Kansas Medical Center	5U13HS338780200	560	-
Childhood Obesity Research Demonstration	93-349			579,926	277,389
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93-421	National Association For Chronic Disease Director	5NU380T0002863	202,703	-
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	93-421	National Association For Chronic Disease Director	5NU380T0002864	100,180	72,500
National Organizations for Chronic Disease Prevention and Health Promotion	93-809	National Association For Chronic Disease Director	1NU58DP00651002	25,640	-
National Organizations for Chronic Disease Prevention and Health Promotion	93-809	National Association For Chronic Disease Director	5NU58DP00651003	38,394	-
National Organizations for Chronic Disease Prevention and Health Promotion	93-809	National Association For Chronic Disease Director	5NU58DP00651004	143,322	-
Capacity Building Assistance for High-Impact HIV Prevention	93-834			744,147	93,650
Sexually Transmitted Diseases (STD) Provider Education Grants	93-978			539,125	20,327
Centers for Disease Control	93.RD			835,407	63,726
COVID19-Centers for Disease Control	93.RD			560,304	-
COVID19-Centers for Disease Control	93.RD	Rainmakers Strategic Solutions	Unknown	12,932	-
Centers for Disease Control	93.RD	St. Louis County	HE2021-0178	105,502	-
Centers for Disease Control	93.RD	St. Louis County	DP18-1817	157,308	56,316
COVID19-Centers for Disease Control	93.RD	Task Force for Global Health	NU380T000316	11,618	-
COVID19-Centers for Disease Control	93.RD	University Of Alabama Birmingham	75D30120C9617	30,633	-
Centers for Disease Control	93.RD	Vanderbilt University Medical Center	200-2016-91801	97,166	-
Centers for Disease Control	93.RD	Vanderbilt University Medical Center	75D30122C12914	73,014	-
Centers for Disease Control	93.RD	Wayne State University	WSU22027	29,254	-
Department of Health and Human Services					
Department of Health and Human Services	93.RD			5,054	-
Accountable Health Communities	93-650	University Of Kentucky	1P1CMS3315810503	71,130	-
Food and Drug Administration					
Food and Drug Administration_Research	93.103	Columbia University	5R01FD00574503	3,400	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2022

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Food and Drug Administration_Research	93-103	New York Medical College	5R01FD00636302	3,537	-
Food and Drug Administration_Research	93-103	New York Medical College	5R01FD00636303	25,472	-
Health Resources and Services Administration					
Rural Health Research Centers	93-155	University of Iowa	5U1CRH20419-13-00	90,415	-
Rural Health Research Centers	93-155	University of Iowa	2U1CRH20419-12-00	9,868	-
Mental and Behavioral Health Education and Training Grants	93-732			720,708	-
IMMED Office of the Secretary of Health and Human Services					
Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development	93-360	Integrated Biotherapeutics Inc	IDSEP160030-02	20,594	-
National Institutes of Health					
Environmental Health	93-113			2,621,224	336,594
Environmental Health	93-113	Colorado State University	5R01ES03093703	123,654	-
Environmental Health	93-113	Johns Hopkins University	5R01ES02696102	10,881	-
Environmental Health	93-113	Columbia University	5R01ES03061603	6,221	-
Environmental Health	93-113	University of Louisville	5R01ES02984603	101,322	-
Oral Diseases and Disorders Research	93-121			748,246	132,647
Oral Diseases and Disorders Research	93-121	Kaiser Foundation	3U01DE02872702S1	101,356	-
Oral Diseases and Disorders Research	93-121	TetraImaging, LLC	1R1DE02972701A1	20,774	-
Oral Diseases and Disorders Research	93-121	University of Alabama Birmingham	3U19DE02871702S1	73,558	-
Oral Diseases and Disorders Research	93-121	University of Alabama Birmingham	5U19DE028717-03	101,906	-
Oral Diseases and Disorders Research	93-121	University of Illinois Chicago	7R01DE02647104	70,048	-
Oral Diseases and Disorders Research	93-121	University of Louisville	5R01DE02829603	32,524	-
NIEHS Superfund Hazardous Substances_Basic Research and Education	93-143	University of Louisville	5P42ES02371605	85,937	-
Human Genome Research	93-172			6,177,731	1,813,570
Human Genome Research	93-172	California Institute Of Technology	U24HG002223	36,066	-
Human Genome Research	93-172	Geisinger Clinic	5R01HG00967104	17,878	-
Human Genome Research	93-172	Harvard University	5U01HG00753006	882	-
Human Genome Research	93-172	The Broad Institute Inc	5U24HG01026204	122,842	-
Human Genome Research	93-172	University of California, Santa Cruz	3U01HG01097103S1	578,846	-
Human Genome Research	93-172	University of California, Santa Cruz	5U01HG01097102	99,707	-
Human Genome Research	93-172	University Of North Carolina Chapel Hill	2U24HG00965005	76,468	-
Research Related to Deafness and Communication Disorders	93-173			5,761,261	450,511
Research Related to Deafness and Communication Disorders	93-173	Boystown National Research Hospital	5R01DC01538505	28,692	-
Research Related to Deafness and Communication Disorders	93-173	Boystown National Research Hospital	5R01DC01833003	4,232	-
Research Related to Deafness and Communication Disorders	93-173	Cincinnati Children's Hospital Medical Center	5R01DC01786702	14,737	-
Research Related to Deafness and Communication Disorders	93-173	East Carolina University	5R01DC01770202	11,321	-
Research Related to Deafness and Communication Disorders	93-173	Ohio State University	5U01DC01892002	121,505	-
Research Related to Deafness and Communication Disorders	93-173	Ohio State University	U01DC018920	7,497	-
Research Related to Deafness and Communication Disorders	93-173	University of Alabama Birmingham	5R01DC01598005	233,995	-
Research Related to Deafness and Communication Disorders	93-173	University of Iowa	5R01DC01848803	111,021	-
Research Related to Deafness and Communication Disorders	93-173	University of Nevada at Reno	5P01AG05144305	45,242	45,242
Research Related to Deafness and Communication Disorders	93-173	University of Pittsburgh	2R01DC01304806A1	63,163	-
Research Related to Deafness and Communication Disorders	93-173	University of Pittsburgh	5R01HD07951208	38,806	-
Research Related to Deafness and Communication Disorders	93-173	University Of Southern California	5R01DC01774102	5,933	-
Research Related to Deafness and Communication Disorders	93-173	University of Utah	2R01DC01131108	15,481	-
Research Related to Deafness and Communication Disorders	93-173	University of Utah	5R01DC01131110	1,811	-
Research Related to Deafness and Communication Disorders	93-173	Vanderbilt University	2RM1HG009034	82,470	-
Research and Training in Complementary and Integrative Health	93-213			2,217,337	88,762
Research and Training in Complementary and Integrative Health	93-213	Yale University	5R01AT01141902	178,953	-
National Center on Sleep Disorders Research	93-233			686,259	-
Mental Health Research Grants	93-242			38,596,377	5,902,609
Mental Health Research Grants	93-242	Centre for Addiction and Mental Health	5R01MH11831103	6,218	-
Mental Health Research Grants	93-242	Chapman University	5P50MH09688908	34,442	-
Mental Health Research Grants	93-242	Childrens Hospital Los Angeles	7R01MH12146203	83,748	-
Mental Health Research Grants	93-242	Emory University	5R01MH11469205	56,885	-
Mental Health Research Grants	93-242	Emory University	5R01MH11828503	7,874	-
Mental Health Research Grants	93-242	Geisinger Clinic	5U01MH11970502	67,114	-
Mental Health Research Grants	93-242	Geisinger Clinic	5U01MH11970503	333,671	-
Mental Health Research Grants	93-242	Harvard University	Unknown	5,957	-
Mental Health Research Grants	93-242	Institute of Mental Hygiene	5P50MH11584304	63,690	-
Mental Health Research Grants	93-242	Kitware Inc	2R42MH11884503	186,945	-
Mental Health Research Grants	93-242	Mayo Clinic	5R01MH12225803	56,490	-
Mental Health Research Grants	93-242	NeuroLux	2R42HM11652502	207,939	-
Mental Health Research Grants	93-242	NeuroLux	2R44MH11494403A1	32,438	-
Mental Health Research Grants	93-242	NeuroLux	5R44MH11494404	108,626	-
Mental Health Research Grants	93-242	New York University	5P50MH11366202	226,499	-
Mental Health Research Grants	93-242	New York University	5P50MH11366203	30,538	-
Mental Health Research Grants	93-242	Northwestern University	5R01M12187703	565,616	-
Mental Health Research Grants	93-242	Nous Imaging Inc	1R44MH12127601A1	39,902	-
Mental Health Research Grants	93-242	Nous Imaging Inc	1R44MH12456701	32,647	-
Mental Health Research Grants	93-242	Nous Imaging Inc	4R44MH12127602	60,154	-
Mental Health Research Grants	93-242	Nous Imaging Inc	4R44MH12456702	88,526	-
Mental Health Research Grants	93-242	Nous Imaging Inc	5R44MH12206603	132,651	-
Mental Health Research Grants	93-242	Pennsylvania State University	1R01MH13000701	14,382	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2022

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Mental Health Research Grants	93-242	Pennsylvania State University	R56MH126349	51,016	-
Mental Health Research Grants	93-242	Regents Of The University Of Minnesota	5R01MH0967310	777,846	-
Mental Health Research Grants	93-242	Regents Of The University Of Minnesota	5R01MH1696104	37,629	-
Mental Health Research Grants	93-242	Rutgers The State University Of NJ	5U524MH06845719	14,091	-
Mental Health Research Grants	93-242	Rutgers The State University Of NJ	5U524MH06845720	6,474	-
Mental Health Research Grants	93-242	St. Louis College of Pharmacy	5R01MH09276911	16,811	-
Mental Health Research Grants	93-242	The Miriam Hospital	5R01MH11465705	123,305	-
Mental Health Research Grants	93-242	The Regents of the University of California	1R24MH12916601	16,470	-
Mental Health Research Grants	93-242	The Regents of the University of California	5R01MH10734505	12,082	-
Mental Health Research Grants	93-242	The Regents of the University of California	1R01MH11821702	219,613	-
Mental Health Research Grants	93-242	Trustees Of Columbia University In The City Of New York	1R01MH12231901A1	34,083	-
Mental Health Research Grants	93-242	Trustees Of Columbia University In The City Of New York	1R01MH12059701	1,684	-
COVID19-Mental Health Research Grants	93-242	Trustees Of Columbia University In The City Of New York	R01MH120597	6,624	-
Mental Health Research Grants	93-242	Universidad de O'Higgins	1U01MH11550201	(2,203)	-
Mental Health Research Grants	93-242	Universidad de O'Higgins	5R01MH11550204	61,044	-
Mental Health Research Grants	93-242	University Of Alabama Birmingham	5R34MH12110303	13,998	-
Mental Health Research Grants	93-242	University Of California Davis	5R01MH120555-03	17,029	-
Mental Health Research Grants	93-242	University Of California Los Angeles	5R01MH10062715	250,236	-
Mental Health Research Grants	93-242	University Of Connecticut	7R61MH11831104	30,549	-
Mental Health Research Grants	93-242	University Of Illinois Chicago	1RF1MH1923701A1	52,058	-
Mental Health Research Grants	93-242	University Of Maryland	1RF1MH12316301A1	13,264	-
Mental Health Research Grants	93-242	University Of Missouri at St. Louis	5R01MH10855904	113,269	-
Mental Health Research Grants	93-242	University Of North Carolina Chapel Hill	5U01MH11092505	14,802	-
Mental Health Research Grants	93-242	University Of North Carolina Chapel Hill	5U01MH11092505	1,203	-
Mental Health Research Grants	93-242	University Of Rochester	SUB00000364/UR FAO GR532180	44,653	-
Mental Health Research Grants	93-242	Yale University	Unknown	3,563	-
Mental Health Research Grants	93-242	Yale University	5R01MH11274604	(945)	-
Mental Health Research Grants	93-242	Yale University	5U01MH112463902	367,388	-
Alcohol Research Programs	93-273			2,117,973	161,727
Alcohol Research Programs	93-273	RTI International	1R01AA02704901A1	49,862	-
COVID19-Alcohol Research Programs	93-273	State University Of New York	1R01AA02991401	3,921	-
Alcohol Research Programs	93-273	State University Of New York	5U10AA00840132	184,616	-
Alcohol Research Programs	93-273	State University Of New York	5U10AA00840133	916,554	-
Alcohol Research Programs	93-273	University Of California, San Francisco	5R34AA02798302	29,830	-
Alcohol Research Programs	93-273	University Of Missouri System	5R01AA02782403	115,372	-
Drug Abuse and Addiction Research Programs	93-279			14,456,388	2,190,684
Drug Abuse and Addiction Research Programs	93-279	Bentley Technologies Inc	1R43DA04697401	2,559	-
Drug Abuse and Addiction Research Programs	93-279	Childrens Hospital Los Angeles	5U01DA03692607	427,068	-
Drug Abuse and Addiction Research Programs	93-279	George Washington University	1R56DA05123201A1	7,350	-
Drug Abuse and Addiction Research Programs	93-279	George Washington University	22-M24	14,258	-
Drug Abuse and Addiction Research Programs	93-279	Intra-Cellular Therapies Inc	Unknown	162,012	-
Drug Abuse and Addiction Research Programs	93-279	Johns Hopkins University	5R21DA4779502	4,739	-
Drug Abuse and Addiction Research Programs	93-279	Johns Hopkins University	5RFA0305974502	116,990	-
Drug Abuse and Addiction Research Programs	93-279	New York University	4UH3CA261067-02	8,928	-
Drug Abuse and Addiction Research Programs	93-279	Ohio State University	5R01DA05302803	118,571	-
Drug Abuse and Addiction Research Programs	93-279	RTI International	5R01DA04209003	50,741	-
Drug Abuse and Addiction Research Programs	93-279	RTI International	5R01DA04401405	122,361	-
Drug Abuse and Addiction Research Programs	93-279	Saint Louis University	5R01DA04381104	35,658	-
Drug Abuse and Addiction Research Programs	93-279	St. Louis College of Pharmacy	5R21DA04865002	(2,557)	-
Drug Abuse and Addiction Research Programs	93-279	The Miriam Hospital	5R25DA03719007	1,854	-
Drug Abuse and Addiction Research Programs	93-279	The Regents of the University of California	1U24DA05532501	39,201	-
Drug Abuse and Addiction Research Programs	93-279	The Regents of the University of California	3U24DA04112307S1	128,863	-
Drug Abuse and Addiction Research Programs	93-279	The Regents of the University of California	3U24DA04114706S2	27,492	-
Drug Abuse and Addiction Research Programs	93-279	The Regents of the University of California	5U24DA04112308	2,306	-
Drug Abuse and Addiction Research Programs	93-279	University Of Chicago	5UH3DA04482904	1,558	-
Drug Abuse and Addiction Research Programs	93-279	University Of Chicago	5UH3DA04482905	5,452	-
Drug Abuse and Addiction Research Programs	93-279	University Of North Carolina Chapel Hill	5R01DA04787604	27,234	-
Drug Abuse and Addiction Research Programs	93-279	Yale University	3UG1DA01583120S2	122,019	-
Drug Abuse and Addiction Research Programs	93-279	Yale University	5UG1DA01583121	29,645	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286			8,327,742	229,294
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286	Albany Research Institute	5P41EB01878309	585,644	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286	Albany Research Institute	NS108916	13,038	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286	Boston Children's Hospital	GENFD0002156105	11,513	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286	Cornell University	5R01EB02925903	132,789	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286	Florida International University	5R01EB02758402	11,209	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286	Georgia Institute Of Technology	1R01EB02985201	149,671	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286	Illinois Institute of Technology	5R01EB02980002	132,554	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286	Kitware Inc	5R01EB02139602	2,970	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286	New York Medical College	5R01EB02831903	10,322	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286	University Of Connecticut	1U01HL15634901	4,675	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286	University Of Connecticut	5U01HL15634903	90,779	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286	University Of Delaware	5R01EB02757703	239,847	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286	University Of Illinois at Urbana-Champaign	5R01EB02865203	92,062	-
Minority Health and Health Disparities Research	93-307			1,186,156	96,397

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2022

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Minority Health and Health Disparities Research	93-307	Northwestern University	5R01MD01174904	62,300	-
Minority Health and Health Disparities Research	93-307	Rector & Visitors Of The University Of Virginia	5R01MD00770207	32,687	-
Minority Health and Health Disparities Research	93-307	University Of North Carolina Chapel Hill	1R01MD01510901A1	62,405	-
Minority Health and Health Disparities Research	93-307	University Of Southern California	5R01MD01225205	53,235	-
Minority Health and Health Disparities Research	93-307	University Of Southern California	5R21MD01594502	11,594	-
Trans-NIH Research Support	93-310			8,249,659	1,266,335
COVID-19-Trans-NIH Research Support	93-310			782,505	-
Trans-NIH Research Support	93-310	Duke University	3UCOD02337504S1	58,102	-
Trans-NIH Research Support	93-310	Duke University	5U2COD02337503	25,279	-
Trans-NIH Research Support	93-310	Florida State University	1R01MD01740401	14,158	-
Trans-NIH Research Support	93-310	Harvard University	5U01HG00753008	139,636	-
Trans-NIH Research Support	93-310	Regents Of The University Of Michigan	3U2CES03016404S1	22,384	-
Trans-NIH Research Support	93-310	The Board Of Trustees Of The Leland Stanford Junior University	5U54HG01042602	8,587	-
Trans-NIH Research Support	93-310	The Board Of Trustees Of The Leland Stanford Junior University	5U54HG01042604	139,121	-
Trans-NIH Research Support	93-310	The Brigham And Women's Hospital Inc	5UH3OD02326805	75,284	-
Trans-NIH Research Support	93-310	The Brigham And Women's Hospital Inc	5UH3OD02326806	334,712	-
Trans-NIH Research Support	93-310	The Regents of the University of California	3 U54 HL145608-04S2	99,907	-
Trans-NIH Research Support	93-310	The Regents of the University of California	5U54HL14560803	1,268	-
Trans-NIH Research Support	93-310	The Regents of the University of California	5U54HL14560804	371,156	-
Trans-NIH Research Support	93-310	The Regents of the University of California	5U01HG01158502	146,248	-
Trans-NIH Research Support	93-310	University of Melbourne	3R01AG05867604S1	19,284	-
Trans-NIH Research Support	93-310	University of Nevada, Las Vegas	1U01OD03323901	5,991	-
Trans-NIH Research Support	93-310	University Of North Carolina Chapel Hill	5U24DK11620403	45,272	-
Trans-NIH Research Support	93-310	University Of North Carolina Chapel Hill	5U24DK11620404	262,893	-
Trans-NIH Research Support	93-310	University Of Wisconsin	5U24DK11620405	189,783	-
Trans-NIH Research Support	93-310	University Of Wisconsin	5UH3OD02328205	144,761	-
Trans-NIH Research Support	93-310	University Of Wisconsin	5UH3OD02328206	647,419	-
National Center for Advancing Translational Sciences	93-350			13,376,734	1,349,570
National Center for Advancing Translational Sciences	93-350	Baylor College of Medicine	1 UC3TR003908	10,392	-
National Center for Advancing Translational Sciences	93-350	Children's Hospital Corporation	5U01TR00262303	144,916	-
National Center for Advancing Translational Sciences	93-350	Duke University	5U01TR00180303	10,596	-
National Center for Advancing Translational Sciences	93-350	Dystonia Medical Research Foundation	5U4TR0014156	9,851	-
National Center for Advancing Translational Sciences	93-350	Harvard University	3UL1TR00254104S2	30,972	-
National Center for Advancing Translational Sciences	93-350	Harvard University	5U01TR00254105	5,626	-
National Center for Advancing Translational Sciences	93-350	Northwestern University	1U01TR00352801	68,026	-
National Center for Advancing Translational Sciences	93-350	Oregon Health & Science University	5U24TR00230604	22,411	-
National Center for Advancing Translational Sciences	93-350	Oregon Health & Science University	5U24TR00230605	9,655	-
National Center for Advancing Translational Sciences	93-350	Precision Virologics Inc	7R41TR00186902	14,828	-
National Center for Advancing Translational Sciences	93-350	University of Colorado Denver	7U24TR002306-05	278,846	-
National Center for Advancing Translational Sciences	93-350	University of Illinois Chicago	3UL1TR00200306S2	11,611	-
National Center for Advancing Translational Sciences	93-350	University Of Iowa	5R21TR00341002	81,488	-
National Center for Advancing Translational Sciences	93-350	Vanderbilt University Medical Center	5U01TR00239802	58,746	-
National Center for Advancing Translational Sciences	93-350	Virginia Commonwealth University	5R21TR00318402	142	-
Research Infrastructure Programs	93-351			3,502,922	444,177
Research Infrastructure Programs	93-351	Cornell University	2P40OD096416	(106)	-
Research Infrastructure Programs	93-351	Cornell University	5P40OD01096416	126,481	-
Research Infrastructure Programs	93-351	Cornell University	5P40OD01096418	10,145	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93-353			6,844,837	98,934
21st Century Cures Act - Beau Biden Cancer Moonshot	93-353	Children's Hospital Of Philadelphia	1U54CA23256801	51,580	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93-353	Duke University	1U2CCA23325401	101,905	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93-353	Fred Hutchinson Cancer Center	5UM1CA154967-11	2,750	-
Nursing Research	93-361			1,219,712	454,810
COVID-19-Nursing Research	93-361			98,267	-
Nursing Research	93-361	Emory University	Unknown	2,243	-
Nursing Research	93-361	Regents Of The University Of Colorado	5U2CNR01463708	(1,166)	-
Nursing Research	93-361	Saint Louis University	3R21NR01797801A1S1	20,064	-
Nursing Research	93-361	University of Pennsylvania School of Medicine	5R01NR01221308	9,526	-
Cancer Cause and Prevention Research	93-393			12,030,457	1,556,044
Cancer Cause and Prevention Research	93-393	Baylor University	5U19CA20365405	38,933	-
Cancer Cause and Prevention Research	93-393	Baylor University	5U19CA20365405	8,737	-
Cancer Cause and Prevention Research	93-393	Harvard University	1R01CA19779906	9,787	-
Cancer Cause and Prevention Research	93-393	Kaiser Permanente	1R01CA26232501	66,364	-
Cancer Cause and Prevention Research	93-393	Massachusetts General Hospital	1R35CA26393401	46,303	-
Cancer Cause and Prevention Research	93-393	Mayo Clinic	5U01CA19556806A1	105,399	-
Cancer Cause and Prevention Research	93-393	Memorial Sloan Kettering Cancer Center	5R01CA22323104	9,289	-
Cancer Cause and Prevention Research	93-393	Northwestern University	5R01CA21843604	31,896	-
Cancer Cause and Prevention Research	93-393	Rockefeller University	2P01CA19653906	173,663	-
Cancer Cause and Prevention Research	93-393	Rockefeller University	SUB00000206	43,402	-
Cancer Cause and Prevention Research	93-393	St. Jude Children's Research Hospital	3U01CA19554706S1	1,079	-
Cancer Cause and Prevention Research	93-393	The Hospital for Sick Children	5R01CA2511202	15,303	-
Cancer Cause and Prevention Research	93-393	Trustees Of The University Of Pennsylvania	5R01CA17490409	6,085	-
Cancer Cause and Prevention Research	93-393	University Of California Berkeley	3P01CA09258419S1	11,517	-
Cancer Cause and Prevention Research	93-393	University Of Connecticut	5R01CA22025404	26,857	-
Cancer Cause and Prevention Research	93-393	University Of Iowa	5R01CA19324906	25,880	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2022

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Cancer Cause and Prevention Research	93-393	University of Massachusetts Amherst	5R01CA22501802	4,085	-
Cancer Cause and Prevention Research	93-393	University of North Carolina at Charlotte	3U01CA2355703S1	1,691	-
Cancer Cause and Prevention Research	93-393	University of North Carolina Chapel Hill	5P01CA22559704	558,742	27,791
Cancer Cause and Prevention Research	93-393	University of Texas MD Anderson Cancer Center	5R01CA22564703	30,298	-
Cancer Cause and Prevention Research	93-393	University of Utah	1U01CA20611005	49,232	-
Cancer Cause and Prevention Research	93-393	University of Utah	2U01CA20611006	153,845	-
Cancer Cause and Prevention Research	93-393	Vanderbilt University Medical Center	5R01CA22500504	10,724	-
Cancer Cause and Prevention Research	93-393	Wake Forest University	5R01CA22607803	165,636	-
Cancer Detection and Diagnosis Research	93-394			9,829,842	2,017,291
Cancer Detection and Diagnosis Research	93-394	Acoustic Range Estimates LLC	2R44CA243764-02A1	8,579	-
Cancer Detection and Diagnosis Research	93-394	Memorial Sloan Kettering Cancer Center	1R01CA24423301A1	42,908	-
Cancer Detection and Diagnosis Research	93-394	Memorial Sloan Kettering Cancer Center	5R01CA24423302	90,510	-
Cancer Detection and Diagnosis Research	93-394	New York University	5U24CA210972	59,952	-
Cancer Detection and Diagnosis Research	93-394	Princeton University	1U24CA26402701	16,847	-
Cancer Detection and Diagnosis Research	93-394	Princeton University	5U24CA21100005	2,126	-
Cancer Detection and Diagnosis Research	93-394	Regents Of The University Of Colorado	1R42CA26204501	92,297	-
Cancer Detection and Diagnosis Research	93-394	Sarya LLC	1R42CA25779701	71,061	-
Cancer Detection and Diagnosis Research	93-394	Trustees Of The University Of Pennsylvania	5R01CA20426105	20,620	-
Cancer Detection and Diagnosis Research	93-394	Trustees Of The University Of Pennsylvania	5R01CA25871702	23,164	-
Cancer Detection and Diagnosis Research	93-394	University Of California Los Angeles	5R01CA24630403	58,212	-
Cancer Detection and Diagnosis Research	93-394	University of Illinois at Urbana-Champaign	1R01CA23387301A1	12,915	-
Cancer Detection and Diagnosis Research	93-394	University Of Miami	5U01CA23336303	28,670	-
Cancer Detection and Diagnosis Research	93-394	University Of Miami	OS00000348	323,221	-
Cancer Detection and Diagnosis Research	93-394	University Of San Francisco	5R01CA21214805	168,659	-
Cancer Detection and Diagnosis Research	93-394	Vanderbilt University Medical Center	5U24CA08636819	1,564	-
Cancer Treatment Research	93-395			13,210,145	1,025,587
Cancer Treatment Research	93-395	Accuronix Therapeutics	2R41CA23985302A1	112,903	-
Cancer Treatment Research	93-395	American College of Radiology	1U24CA18080307IROC	24,526	-
Cancer Treatment Research	93-395	Children's Hospital Of Philadelphia (The)	5R01CA14019813	26,012	-
Cancer Treatment Research	93-395	Duke University	3U01CA18670405S1	146,051	-
Cancer Treatment Research	93-395	ECOG-ACRIN Cancer Research Group	5U01CA18082008	34,077	-
Cancer Treatment Research	93-395	ECOG-ACRIN Cancer Research Group	5U10CA18082009	1,534	-
Cancer Treatment Research	93-395	Johns Hopkins University	5U01CA13744310	42,992	-
Cancer Treatment Research	93-395	Medical Guidance Systems, LLC	2R44CA21068702A1	44,549	-
Cancer Treatment Research	93-395	Memorial Sloan Kettering Cancer Center	1U01CA23844401A1	6,656	-
Cancer Treatment Research	93-395	Memorial Sloan Kettering Cancer Center	5U01CA23844402	17,936	-
Cancer Treatment Research	93-395	NRG Oncology Foundation Inc	Unknown	15,484	-
Cancer Treatment Research	93-395	NRG Oncology Foundation Inc	5U10CA18086808	10,304	-
Cancer Treatment Research	93-395	NRG Oncology Foundation Inc	5U10CA18086809	16,410	-
Cancer Treatment Research	93-395	Public Health Institute	7U10CA18086608	1,462	-
Cancer Treatment Research	93-395	Public Health Institute	7U10CA22882304	15,315	-
Cancer Treatment Research	93-395	Public Health Institute	U10CA180886	13,522	-
Cancer Treatment Research	93-395	Regents Of The University Of Minnesota	5P01CA11141214	(4,376)	-
Cancer Treatment Research	93-395	Saint Louis University	1R21CA263428-01A1	2,486	-
Cancer Treatment Research	93-395	St. Jude Children's Research Hospital	1U01CA24657001A1	18,039	-
Cancer Treatment Research	93-395	The Brigham And Women's Hospital Inc	3U01CA18082108S2	8,695	-
Cancer Treatment Research	93-395	The Brigham And Women's Hospital Inc	3U10CA180821-09S3	8,633	-
Cancer Treatment Research	93-395	The Children's Hospital Of Philadelphia	5U01CA22882302	164,705	-
Cancer Treatment Research	93-395	The Children's Hospital Of Philadelphia	U10CA180886	45,103	-
Cancer Treatment Research	93-395	The Emmes Company, LLC	2U01CA12194714	116,820	-
Cancer Treatment Research	93-395	University Of Rochester	1R01CA21489001A1	18,616	-
Cancer Treatment Research	93-395	University Of Texas MD Anderson Cancer Center	5R01CA23562203	113,322	-
Cancer Treatment Research	93-395	Vanderbilt University	5R01CA21404305	11,752	-
Cancer Treatment Research	93-395	Yale University	2U01CA18668906	509,441	-
Cancer Treatment Research	93-395	University Of Rochester	61835	110,926	-
Cancer Biology Research	93-396			8,740,314	209,150
Cancer Biology Research	93-396	Baylor University	7R01CA23964502	28,298	-
Cancer Biology Research	93-396	Case Western Reserve University	1P01CA24570501	36,417	-
Cancer Biology Research	93-396	Case Western Reserve University	1P01CA24570501A1	184,880	-
Cancer Biology Research	93-396	Case Western Reserve University	5P01CA24570502	409,143	-
Cancer Biology Research	93-396	North Carolina Central University	5R01CA24423602	207,609	-
Cancer Biology Research	93-396	Ohio State University	5P01CA10073018	786,300	-
Cancer Biology Research	93-396	The Board of Trustees Of The Leland Stanford Junior University	Unknown	46,070	-
Cancer Biology Research	93-396	The Regents of the University of California	1U01CA26703101	176,310	-
Cancer Center Support Grants	93-397			9,576,398	22,056
Cancer Center Support Grants	93-397	Case Western Reserve University	5U54CA16306010	51,337	-
Cancer Center Support Grants	93-397	John Hopkins University	U54CA210173	24,007	-
Cancer Research Manpower	93-398			4,978,829	-
Cancer Control	93-399	Children's Hospital Of Philadelphia	2UG1CA1899506	80,143	-
Cancer Control	93-399	NRG Oncology Foundation	3UG1CA18986706S2	22,352	-
Cardiovascular Diseases Research	93-837			27,540,010	1,976,078
Cardiovascular Diseases Research	93-837	Cedars Sinai Medical Center	5R01HL14994603	15,111	-
Cardiovascular Diseases Research	93-837	Emory University	5R01HL12239207	296	-
Cardiovascular Diseases Research	93-837	Etiometry Inc	5R44HL1734007	12,930	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2022

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Cardiovascular Diseases Research	93.837	Johns Hopkins University	5U01HL09681210	35,799	-
Cardiovascular Diseases Research	93.837	Johns Hopkins University	5U01HL09681211	104,862	-
Cardiovascular Diseases Research	93.837	Joslin Diabetes Center	5R01HL06777317	79,143	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5R01HL13864604	50,015	-
Cardiovascular Diseases Research	93.837	Massachusetts General Hospital	5U01HL12333606	7,010	-
Cardiovascular Diseases Research	93.837	Medical College Of Wisconsin	5R01HL12558004	2,891	-
Cardiovascular Diseases Research	93.837	National Marrow Donor Program	1U24HL138660	1,068	-
Cardiovascular Diseases Research	93.837	New England Research Institutes	1U24HL13569101	10,623	-
Cardiovascular Diseases Research	93.837	New England Research Institutes	5U24HL13569105	17,479	-
Cardiovascular Diseases Research	93.837	New York University	2R01HL04509529A1	176,923	-
Cardiovascular Diseases Research	93.837	New York University	5R01HL04509530	130,317	-
Cardiovascular Diseases Research	93.837	Northwestern University	5R01HL13694203	44,967	-
Cardiovascular Diseases Research	93.837	Ohio State University	1R01HL14858101A1	18,486	-
Cardiovascular Diseases Research	93.837	Ohio State University	5R01HL12885705	2,417	-
Cardiovascular Diseases Research	93.837	Ohio State University	5UH3HL14014403	19,013	-
Cardiovascular Diseases Research	93.837	State University Of New York	5U01HL13155205	109,155	-
Cardiovascular Diseases Research	93.837	Trustees Of The University Of Pennsylvania	5R01HL13490505	25,894	-
Cardiovascular Diseases Research	93.837	Trustees Of The University Of Pennsylvania	5R34HL14692703	8,461	-
Cardiovascular Diseases Research	93.837	UNandUP, LLC (UN&UP)	1R43HL158306-01A1	1,722	-
Cardiovascular Diseases Research	93.837	University Of Alabama Birmingham	2R01HL12033807A1	19,488	-
Cardiovascular Diseases Research	93.837	University Of Alabama Birmingham	5R01HL14914502	353	-
Cardiovascular Diseases Research	93.837	University Of Alabama Birmingham	5R01HL14914503	4,147	-
Cardiovascular Diseases Research	93.837	University Of Alabama Birmingham	5U01HL12033806	16,007	-
Cardiovascular Diseases Research	93.837	University Of California Davis	3UH3HL14180004S1	120,763	-
Cardiovascular Diseases Research	93.837	University Of California Davis	5UH3HL1418002	539,659	-
Cardiovascular Diseases Research	93.837	University Of California, San Francisco	5R25HL12614607	1,008	-
Cardiovascular Diseases Research	93.837	University Of North Carolina Chapel Hill	1R24HL15894701	914	-
Cardiovascular Diseases Research	93.837	University Of North Carolina Chapel Hill	5R01HL15725502	2,615	-
Cardiovascular Diseases Research	93.837	University Of Pennsylvania School Of Medicine	5R01HL14827203	62,908	-
Cardiovascular Diseases Research	93.837	University Of Texas Health Science Center at Houston	5R01HL14502503	29,300	-
Cardiovascular Diseases Research	93.837	University Of Texas Health Science Center at Houston	5R01HL14686003	22,569	-
Cardiovascular Diseases Research	93.837	University Of Washington	1R01HL16182901	56,262	-
Cardiovascular Diseases Research	93.837	University Of Washington	5P01HL15132803	538,200	-
Cardiovascular Diseases Research	93.837	Yale University	5U01HL12551105	2,859	-
Lung Diseases Research	93.838			9,654,603	763,330
Lung Diseases Research	93.838	Cincinnati Children's Hospital Medical Center	5U01HL13474502	3,352	-
Lung Diseases Research	93.838	Cincinnati Children's Hospital Medical Center	5U01HL13474503	39,513	-
COVID-19 Lung Diseases Research	93.838	Columbia University	RTI22312021757166178	221	-
Lung Diseases Research	93.838	Fred Hutchinson Cancer Center	1UG3HL14701101A1	7,461	-
Lung Diseases Research	93.838	Fred Hutchinson Cancer Center	4UH3HL14701102	10,654	-
Lung Diseases Research	93.838	Indiana University	5R01HL14827202	4,200	-
Lung Diseases Research	93.838	NuPeak Therapeutics Inc	1R41HL14952301	10,007	-
Lung Diseases Research	93.838	Rector & Visitors Of The University Of Virginia	R01HL157407	76,562	-
Lung Diseases Research	93.838	Regents Of The University Of Michigan	5R01HL14726103	5,401	-
Lung Diseases Research	93.838	Renovion, Inc.	1R44HL15114401A1	35,121	-
Lung Diseases Research	93.838	RTI International	OT3HL14779801	23,945	-
Lung Diseases Research	93.838	The Brigham And Women's Hospital Inc	5U01HL14600203	72,490	-
Lung Diseases Research	93.838	The Regents of the University of California	OT2HL16184701	5,257	-
Lung Diseases Research	93.838	Trustees Of The University Of Pennsylvania	5U01HL14885703	100,025	-
Lung Diseases Research	93.838	University Of Arizona	5U01HL13004504	(2,054)	-
Lung Diseases Research	93.838	University Of Arizona	5U01HL13004505	692,885	19,341
Lung Diseases Research	93.838	University Of Colorado Denver	5P01HL15296103	17,216	-
Lung Diseases Research	93.838	University Of North Carolina Chapel Hill	5U54HL09645817	10,126	-
Lung Diseases Research	93.838	University Of North Carolina Chapel Hill	5U54HL09645818	120,891	-
Lung Diseases Research	93.838	Wayne State University	1R01HL14824701A1	27,877	-
Lung Diseases Research	93.838	Wayne State University	5R01HL14824704	7,718	-
Blood Diseases and Resources Research	93.839			9,802,406	603,589
Blood Diseases and Resources Research	93.839	Augusta University	2R25HL10636510	2,158	-
Blood Diseases and Resources Research	93.839	Caeli Vascular, LLC	1R41HL15096301A1	6,449	-
Blood Diseases and Resources Research	93.839	Caeli Vascular, LLC	2R42HL15096302A1	205,007	-
Blood Diseases and Resources Research	93.839	Emory University	1UG3HL14856001A1	23,843	-
Blood Diseases and Resources Research	93.839	Emory University	5UG3HL14856002	62,680	-
Blood Diseases and Resources Research	93.839	Medical College Of Wisconsin	1U01HL15985001	8,785	-
Blood Diseases and Resources Research	93.839	Medical College Of Wisconsin	5U01HL14347702	410	-
Blood Diseases and Resources Research	93.839	National Marrow Donor Program	5U24HL13866002	23,314	-
Blood Diseases and Resources Research	93.839	National Marrow Donor Program	5U24HL13866003	(2,236)	-
Blood Diseases and Resources Research	93.839	National Marrow Donor Program	5U24HL13866005	171	-
Blood Diseases and Resources Research	93.839	St. Jude Children's Research Hospital	5U01HL13399604	69,315	-
Blood Diseases and Resources Research	93.839	University Of Alabama Birmingham	5R01HL13389604	32,594	-
Blood Diseases and Resources Research	93.839	University Of Colorado Denver	4R33HL14179403	30,483	-
Blood Diseases and Resources Research	93.839	University Of Pittsburgh	4UH3HL14319202	591	-
Blood Diseases and Resources Research	93.839	University Of Pittsburgh	5UH3HL14319203	46,955	-
Blood Diseases and Resources Research	93.839	Versiti Wisconsin Inc	5P01HL14445703	320,601	-
Blood Diseases and Resources Research	93.839	Versiti Wisconsin Inc	5P01HL14445704	87,447	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2022

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Blood Diseases and Resources Research	93.839	Versiti Wisconsin Inc	5R01HL06883515	53,434	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840			1,842,833	113,823
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	Regional Alliance for Sustainable Development	1U24HL13679004	9,645	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	Universidad Peruana Cayetano Heredia	1UGHL15237101	224,872	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	University of Abuja	5UG3HL15238102	25,406	-
Translation and Implementation Science Research for Heart, Lung, Blood Diseases and Sleep Disorders	93.840	Vanderbilt University	1OT2HL15681201	139,133	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846			14,679,288	607,234
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Biorestorative Therapies Inc	1R41AR0793401	86,869	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Boston University	5R01AR07442804	11,416	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Children's Hospital Of Philadelphia (The)	1R01AR07982201	20	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Hebrew Rehabilitation Center	5R01AR07534602	27,796	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Indiana University	5R01AR07647702	11,102	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Massachusetts General Hospital	5R01AR07601303	39,702	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Northeast Ohio Medical University	5R01AR07776202	65,424	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Steadman Philippon Research Institute	1R21AR07907501A1	3,926	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	The Brigham And Women's Hospital Inc	5R01AR05555712	15,720	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees Of Columbia University In The City Of New York	5R01AR05783609	17,611	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees Of Columbia University In The City Of New York	5R01AR06294709	292,763	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees Of The University Of Pennsylvania	5R01AR06906205	25,970	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Trustees Of The University Of Pennsylvania	5R01AR07087304	41,954	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University Of California Irvine	1R01AR078340	4,127	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University Of Pittsburgh	5R01AR07614603	78,594	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University Of Pittsburgh	5R21AR07524202	7,176	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University Of Southern California	5R01AR07221205	155,614	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	University Of Texas Southwestern Medical Center	1R01AR078311-01A1	35,804	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	Vanderbilt University	5R01AR066084608	159,750	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847			45,015,423	4,322,536
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Ann & Robert H. Lurie Children's Hospital of Chicago	1U01DK12799501	10,191	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Augusta University	5U24DK11525504	137,709	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Bio, LLC	1R42DK12165201A1	276,447	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	5U01DK09415710	9,684	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Case Western Reserve University	5U01DK09415711	171,285	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Cedars Sinai Medical Center	5U01DK06241319	7,760	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Cedars Sinai Medical Center	5U01DK06241320	76,051	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Children's Hospital Of Philadelphia (The)	5R01DK09783007	28,001	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Cleveland Clinic Lerner College of Medicine	5R01DK12279002	426,338	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK06123016	16,897	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK09824608	15,079	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	George Washington University	5U01DK09824609	28,134	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Lung Therapeutics	1R43DK12401001A1	23,490	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	McGill University	5R01DK11073703	43,607	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Medical University of South Carolina	5U01DK11549504	200	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Nationwide Children's Hospital	5U01DK10086609	559	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northern California Institute For Research And Education	1R01DK12564601	5,722	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northern California Institute For Research And Education	5R01DK12564602	78,264	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	5P30DK11485704	1,866	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	5R01DK09221708	72,644	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	5R01DK12574902	33,319	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Northwestern University	60061103 WUSTL	17,572	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	PlatformsTL	5R42DK12025303	248,722	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Rector & Visitors Of The University Of Virginia	5R01DK11186104	11,589	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Regents Of The University Of Michigan	5R01DK10790405	29,118	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Saint Louis University	2R56DK11040606A1	15,217	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Saint Louis University	5R01DK11040606	1,609	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Senseon Therapeutics, Inc.	2R44DK12159802A1	167,125	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Senseon, LLC	1R44DK12660001	154,320	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	State University Of New York	5R01DK11448503	44,078	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Board Of Trustees Of The Leland Stanford Junior University	1U01DK130060	2,755	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Children's Mercy Hospital	2U01DK06614317	3,139	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Medical University Of South Carolina	5U01DK10483306	7,732	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	The Regents of the University of California	128178108 (S9002561)	248,499	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Alabama Birmingham	1R01DK12749701	12,323	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Alabama Birmingham	5P30DK07933715	31,385	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Alabama Birmingham	5R01DK12749702	449,552	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of California, San Francisco	5R01DK11598703	7,119	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of California, San Francisco	5R01DK11598703	35,596	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Chicago	5P01DK05678818	36,967	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Chicago	5U54DK11861203	132,169	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Iowa	2U01DK10833406	1,894	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Iowa	3U01DK10833407S1	2,283	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Iowa	5R01DK11875204	25,083	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Iowa	5U01DK10833407	40,522	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Kansas Medical Center	1R56DK12923401	16,610	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Pennsylvania School of Medicine	1U01DK12665401	72,610	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2022

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of South Florida	1R01DK12532201A1	25,057	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University Of Southern California	3U01DK10735004	1,087	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Washington	5U2CDK11488605	100,335	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	University of Wisconsin	1R01DK1184501A1	197,680	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Vanderbilt University Medical Center	1R01DK1921201	10,380	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Wake Forest University	5R01DK12887102	1,377	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	Weill Medical College of Cornell University	1R01DK12581701A1	20,348	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	XN Biotechnologies, LLC	1R41DK12913801A1	128,924	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853			45,681,147	4,210,362
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Boston University	5U01NS09333406	6,773	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	California Institute Of Technology	5R01NS10227903	63,317	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Childrens Hospital Los Angeles	7R01NS09597906	19,551	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Children's National Health System	5R01NS11229403	21,604	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Cleveland Clinic Foundation	U01NS116776	20,106	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Duke University	5R01NS1158803	50,836	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Emory University	5U54NS1602510	409,918	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	FreeFlow Medical Device LLC	2R42NS10370402A1	430,857	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Hugo W Moser Research Institute at Kennedy Krieger Inc	5K12NS09848204	119,511	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Hugo W Moser Research Institute at Kennedy Krieger Inc	5K12NS09848205	120,991	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Johns Hopkins University	5U01NS11167802	114,780	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Johns Hopkins University	5U01NS11167803	42,000	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5R01NS11760903	65,632	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	5U01NS11400102	28,151	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	U01NS111029	48,653	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Massachusetts General Hospital	U01NS0953388	33,476	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Minnetronix	5R44NS1024703	12,936	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mitochondria in Motion Inc	1R41NS11364201	10,254	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Mitochondria in Motion Inc	2R42NS11518402	102,846	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	National Institute for Health Research	1K08NS11788801A1	11,593	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	New York University	5R01NS10169602	27,376	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Northwestern University	1R01NS12586301A1	7,372	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Northwestern University	5U01NS11385102	124	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Ohio State University	Unknown	80,164	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Oregon Health & Science University	1015486 - WUSTL	190,858	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Phoenix Nest Inc	2U44NS08906105	26,787	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Rector & Visitors Of The University of Virginia	5R01NS09911804	49,531	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Regents Of The University of Colorado	1U01NS11431201A1	27,438	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Research Foundation of the City University of New York	1R01NS11801201A1	14,283	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Research Foundation of the City University of New York	5R01NS11801202	3,444	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Rhaeos Inc	1U44NS12155501	86,662	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Rutgers The State University Of NJ	2U24NS09591406	15,858	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Rutgers The State University Of NJ	5U24NS09591407	181,522	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Saint Louis University	5R01NS11428903	70,371	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	St. Jude Children's Research Hospital	1R01NS11211401	177,267	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	St. Louis College of Pharmacy	1R34NS126036-01	41,257	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of Columbia University In The City Of New York	5R01NS11082601A1	(15,506)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of Columbia University In The City Of New York	5R01NS11028602	59,430	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of Columbia University In The City Of New York	5R21NS11306303	1,802	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of The University of Pennsylvania	5R01NS11586902	15,487	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of The University of Pennsylvania	5U19NS11045602	346,727	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	Trustees Of The University of Pennsylvania	5U19NS11045603	524,917	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Alabama Birmingham	5U01NS09259504	21,391	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	1U54NS12083601	121,821	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	1U54NS12398501	70,442	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of California, San Francisco	5U01NS09276405	27,341	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Chicago	1R01NS11626201A1	19,808	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Chicago	5R01NS11626202	19,238	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS09904301A1	33,280	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS10228901A1	6,511	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS10651301A1	5,434	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS10665501A1	128,691	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS1072801	1,538	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS1077201	2,591	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	1U01NS117450-01A1	349	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	5U01NS09586902	13,758	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	5U01NS10069902	23,641	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Cincinnati	7U01NS10069903	4,148	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Miami	1U24NS12085801	63,170	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of North Carolina Chapel Hill	1R01NS12223001	168,917	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University Of Rochester	5R01NS11199702	107,226	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Southern California	5R01NS03446723	222,930	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Texas Health Science Center at Houston	1R61NS11332901	8,093	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Utah	10050533-10	80,106	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	University of Utah	1U01NS10748601A1	16,872	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2022

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Extramural Research Programs in the Neurosciences and Neurological Disorders	93-853	University of Washington	5R01NS09161807	40,365	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93-853	Vanderbilt University	1UG3NS11621801	35,600	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93-853	Vanderbilt University	4U13NS11621802	45,493	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93-853	Wayne State University	5R01NS09457004	(8,906)	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93-853	Weill Medical College of Cornell University	5R01NS1199703	46,117	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93-853	Weill Medical College of Cornell University	5U54NS10071704	2,639	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93-853	Yale University	5R01NS1102902	(19,051)	-
Allergy and Infectious Diseases Research	93-855			62,736,954	10,028,997
Allergy and Infectious Diseases Research	93-855	Albert Einstein College of Medicine	1R01AI158194-01A1	41,736	-
Allergy and Infectious Diseases Research	93-855	Alberta Health Services	1R01AI165327-01	59,881	-
Allergy and Infectious Diseases Research	93-855	Baylor College of Medicine	2R01AI03295630	12,105	-
Allergy and Infectious Diseases Research	93-855	Benaroya Research Institute At Virginia Mason	2UM1AI10955508	78,793	-
Allergy and Infectious Diseases Research	93-855	Benaroya Research Institute At Virginia Mason	5UM1AI10955509	52,979	-
Allergy and Infectious Diseases Research	93-855	Boston Children's Hospital	1R56AI16301301	7,483	-
Allergy and Infectious Diseases Research	93-855	Boston University	1R21AI15623601	25,725	-
Allergy and Infectious Diseases Research	93-855	Case Western Reserve University	5R21AI13989802	19,898	-
Allergy and Infectious Diseases Research	93-855	Children's Hospital Corporation	5U01AI12661402	1,038	-
Allergy and Infectious Diseases Research	93-855	Children's Hospital Corporation	5U01AI12661406	121,109	-
Allergy and Infectious Diseases Research	93-855	Children's Hospital Los Angeles	1U01AI12661201A1	8,102	-
Allergy and Infectious Diseases Research	93-855	Cleveland Clinic Lerner College of Medicine	7R01AI1277406	51,429	-
Allergy and Infectious Diseases Research	93-855	Cleveland Clinic Lerner College of Medicine	5R01AI1277404	32,343	-
Allergy and Infectious Diseases Research	93-855	Drexel University	5U19AI12891005	24,151	-
Allergy and Infectious Diseases Research	93-855	Drexel University	5U19AI12891004	1,647	-
Allergy and Infectious Diseases Research	93-855	Duke University	1U01AI16309901	44,603	-
Allergy and Infectious Diseases Research	93-855	Duke University	5R01AI14582804	177,800	-
Allergy and Infectious Diseases Research	93-855	Emory University	1U01AI15074701	512	-
Allergy and Infectious Diseases Research	93-855	Emory University	3U19AI11048308S4	53,383	-
Allergy and Infectious Diseases Research	93-855	Emory University	5R01AI12520201	46,678	-
Allergy and Infectious Diseases Research	93-855	Emory University	5U01AI15074703	5,035	-
Allergy and Infectious Diseases Research	93-855	Emory University	A540588	188,608	-
Allergy and Infectious Diseases Research	93-855	Family Health International	UM1AI066819	749,008	-
Allergy and Infectious Diseases Research	93-855	Fibrotron Therapeutics Inc	2R44AI14983303	125,370	-
Allergy and Infectious Diseases Research	93-855	Fibrotron Therapeutics Inc	5R43AI14983302	45,272	-
Allergy and Infectious Diseases Research	93-855	Forward Defense LLC	1R41AI16713701A1	10,682	-
Allergy and Infectious Diseases Research	93-855	Fox Chase Cancer Center	1R56AI15096501A1	157,203	-
Allergy and Infectious Diseases Research	93-855	Fred Hutchinson Cancer Center	3UM1AI066861415S1	93,972	-
Allergy and Infectious Diseases Research	93-855	Icahn School Of Medicine At Mount Sinai	1R01AI168178-01	5,217	-
Allergy and Infectious Diseases Research	93-855	Icahn School Of Medicine At Mount Sinai	2U01AI06359418	13,618	-
Allergy and Infectious Diseases Research	93-855	Icahn School Of Medicine At Mount Sinai	5U01AI06359417	6,197	-
Allergy and Infectious Diseases Research	93-855	Icahn School Of Medicine At Mount Sinai	HHSNS72201400008C	734,008	-
Allergy and Infectious Diseases Research	93-855	Integrated BioTherapeutics Inc	1R41AI5274501A1	154,731	-
Allergy and Infectious Diseases Research	93-855	La Jolla Institute for Immunology	5U19AI14279003	595,173	-
Allergy and Infectious Diseases Research	93-855	La Jolla Institute for Immunology	5U19AI14279004	88,963	-
Allergy and Infectious Diseases Research	93-855	Los Angeles Biomedical Research Institute	1U01AI11640003	633	-
Allergy and Infectious Diseases Research	93-855	Los Angeles Biomedical Research Institute	5U01AI11640004	53,200	-
Allergy and Infectious Diseases Research	93-855	Massachusetts General Hospital	1U01AI16308601	28,935	-
Allergy and Infectious Diseases Research	93-855	Michigan State University	5U01AI12661004	11,706	-
Allergy and Infectious Diseases Research	93-855	Michigan State University	5U01AI12661006	16,276	-
Allergy and Infectious Diseases Research	93-855	Northwestern University	5P30AI11794307 Revised	10,320	-
Allergy and Infectious Diseases Research	93-855	Oregon Health & Science University	5R01AI13218605	244,534	-
Allergy and Infectious Diseases Research	93-855	Oregon Health & Science University	5R21AI14465802	3,777	-
Allergy and Infectious Diseases Research	93-855	Regents Of The University Of Colorado	5R01AI14143602	257,788	-
Allergy and Infectious Diseases Research	93-855	Saint Louis University	1R01AI13019001A1	6,705	-
Allergy and Infectious Diseases Research	93-855	Saint Louis University	5U01AI13019002	33,687	-
Allergy and Infectious Diseases Research	93-855	St. Jude Children's Research Hospital	3U01AI14461603S1	442,479	-
Allergy and Infectious Diseases Research	93-855	St. Jude Children's Research Hospital	1U01AI144616	33,443	-
Allergy and Infectious Diseases Research	93-855	Temple University	1UM1AI16456801	501,458	-
Allergy and Infectious Diseases Research	93-855	Texas Tech University System	1R15AI15674601A1	10,386	-
Allergy and Infectious Diseases Research	93-855	The Board Of Trustees Of The Leland Stanford Junior University	3U01AI13595003S1	57,083	-
Allergy and Infectious Diseases Research	93-855	The Jackson Laboratory	5U19AI14273303	196,729	-
Allergy and Infectious Diseases Research	93-855	The Regents of the University of California	5R01AI11463508	25,659	-
Allergy and Infectious Diseases Research	93-855	The Regents of the University of California	7R21AI15204902	46,378	-
Allergy and Infectious Diseases Research	93-855	The Salk Institute for Biological Studies	5R01AI1040006	265,807	-
Allergy and Infectious Diseases Research	93-855	Trustees Of The University Of Pennsylvania	5R01AI14053905	233,830	-
Allergy and Infectious Diseases Research	93-855	University Of Alabama Birmingham	1U54AI15022501	867	-
Allergy and Infectious Diseases Research	93-855	University Of Alabama Birmingham	5U19AI14275903	221,103	-
Allergy and Infectious Diseases Research	93-855	University Of Alabama Birmingham	5U19AI14275904	87,822	-
Allergy and Infectious Diseases Research	93-855	University Of Arizona	UM1AI12994505	2,028	-
Allergy and Infectious Diseases Research	93-855	University Of California Los Angeles	UM1AI066836	158,627	-
Allergy and Infectious Diseases Research	93-855	University Of California Los Angeles	3UM1AI066836-14S2	60,788	-
Allergy and Infectious Diseases Research	93-855	University Of California, San Francisco	1P01AI15539301A1	179,131	-
Allergy and Infectious Diseases Research	93-855	University Of Florida	5R01AI14147804	26,869	-
Allergy and Infectious Diseases Research	93-855	University Of Kentucky	3R01AI140758-04S1	92,694	-
Allergy and Infectious Diseases Research	93-855	University Of Kentucky	5R01AI14075804	320,311	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2022

Cluster Title/Federal Grantor/Program Title	Assistance	Pass Through Entity	Pass-through Entity	Total	Passed to
	Listing Number		Identification Number		
Allergy and Infectious Diseases Research	93.855	University of Louisville	1R01AI3967101A1	9,293	-
Allergy and Infectious Diseases Research	93.855	University of Mississippi	5R21AI14221003	34,532	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh	1R21AI163606-02	144,089	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh	5R01AI12334807	97,795	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh	5R01AI14266203	9,612	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh	5R01AI14582802	5,240	-
Allergy and Infectious Diseases Research	93.855	University of Pittsburgh School of Medicine	5R01AI15021403	69,236	-
Allergy and Infectious Diseases Research	93.855	University of Texas	5R21AI12950502	28,967	-
Allergy and Infectious Diseases Research	93.855	University of Texas Medical Branch	5R01AI14635302	183,227	-
Allergy and Infectious Diseases Research	93.855	University of Texas Southwestern	5U19AI14278403	506,645	-
Allergy and Infectious Diseases Research	93.855	University of Texas Southwestern	5U19AI14278404	251,244	-
Allergy and Infectious Diseases Research	93.855	University of Washington	5R01AI1459603	198,969	-
Allergy and Infectious Diseases Research	93.855	University of Washington	5R01AI1459604	44,412	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin	1UM1AI16004001	422,090	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin	5R01AI13213202	55,470	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin	5R01AI13251904	28,674	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin	5R01AI13864704	30,036	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin	5R01AI15067802	288,933	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin	5R01AI15313002	99,614	-
Allergy and Infectious Diseases Research	93.855	University of Wisconsin	5UM1AI1427107	43,830	-
Allergy and Infectious Diseases Research	93.855	Yanderbilt University	5UM1AI148452-03	45,393	-
Allergy and Infectious Diseases Research	93.855	Yanderbilt University	5UM1AI14845202	21,938	-
Allergy and Infectious Diseases Research	93.855	Yanderbilt University Medical Center	Unknown	433,088	-
Allergy and Infectious Diseases Research	93.855	Yanderbilt University Medical Center	2UM1AI06943916	382,206	-
Allergy and Infectious Diseases Research	93.855	Yanderbilt University Medical Center	3UM1AI14845203S3	459,543	-
Allergy and Infectious Diseases Research	93.855	Yanderbilt University Medical Center	501AI12782805	294,980	-
Allergy and Infectious Diseases Research	93.855	Yanderbilt University Medical Center	5UM1AI06861912	194,542	-
Allergy and Infectious Diseases Research	93.855	Yanderbilt University Medical Center	5UM1AI06943917	208,285	-
COVID19-Allergy and Infectious Diseases Research	93.855	Yanderbilt University Medical Center	UM1AI068619	53,417	-
Allergy and Infectious Diseases Research	93.855	YaxNewMo, LLC	1R1AI16707801	92,740	-
Allergy and Infectious Diseases Research	93.855	Washington State University	1U01AI151799	72,711	-
Biomedical Research and Research Training	93.859			32,642,768	508,815
Biomedical Research and Research Training	93.859	BioRankings LLC	1R43GM14230501	47,245	-
Biomedical Research and Research Training	93.859	BioRankings LLC	2R44GM13148702	9,520	-
Biomedical Research and Research Training	93.859	Cornell University	1R25GM14207001	2,272	-
Biomedical Research and Research Training	93.859	Florida International University	5R01GM13424703	36,913	-
Biomedical Research and Research Training	93.859	GenNext Technologies Inc	1R43GM14235101	30,999	-
Biomedical Research and Research Training	93.859	Protein Metrics Inc	2R42GM12113302	180,792	-
Biomedical Research and Research Training	93.859	Regents Of The University Of Colorado	5R01GM12374604	44,023	-
Biomedical Research and Research Training	93.859	Regents Of The University Of Michigan	5R13GM11784503	2,313	-
Biomedical Research and Research Training	93.859	Regents Of The University Of Michigan	5U54AI15047909	19,306	-
Biomedical Research and Research Training	93.859	Regents Of The University Of Michigan	5U54AI15047910	88,270	-
Biomedical Research and Research Training	93.859	Saint Louis University	1R01GM134081	26,948	-
Biomedical Research and Research Training	93.859	The Jackson Laboratory	5R01GM12373604	34,058	-
Biomedical Research and Research Training	93.859	University Of Alabama Birmingham	5R25GM13051704	33,220	-
Biomedical Research and Research Training	93.859	University Of Florida	5R01GM13904603	115,212	-
Biomedical Research and Research Training	93.859	University Of North Carolina Chapel Hill	5R01GM13728602	45,953	-
Biomedical Research and Research Training	93.859	University Of Pittsburgh	2R01GM10861805	(8,742)	-
Biomedical Research and Research Training	93.859	University Of Pittsburgh	5R01GM10861807	29,465	-
Biomedical Research and Research Training	93.859	University Of Texas	5R01GM11423706	203,883	-
Biomedical Research and Research Training	93.859	Yanderbilt University	5R01GM11661607	44,440	-
Biomedical Research and Research Training	93.859	University of Connecticut	5R01NS10263306	166,459	-
Child Health and Human Development Extramural Research	93.865			18,315,334	3,471,692
Child Health and Human Development Extramural Research	93.865	Boston Medical Center	5R01HD09506004	24,465	-
Child Health and Human Development Extramural Research	93.865	Boston University	5R01HD07281509	31,098	-
Child Health and Human Development Extramural Research	93.865	Boston University	5R01HD09113005	33,649	-
Child Health and Human Development Extramural Research	93.865	Boston University	5R01HD09244405	135,410	-
Child Health and Human Development Extramural Research	93.865	Childrens Hospital Los Angeles	7R21HD08678403	756	-
Child Health and Human Development Extramural Research	93.865	Johns Hopkins University	5R01HD09769204	18,421	-
Child Health and Human Development Extramural Research	93.865	Medical College Of Wisconsin	1R01HD10460701	25,457	-
Child Health and Human Development Extramural Research	93.865	Medical College Of Wisconsin	5R01HD10460702	5,160	-
Child Health and Human Development Extramural Research	93.865	Nationwide Children's Hospital	5R01HD09134703	5,532	-
Child Health and Human Development Extramural Research	93.865	Nationwide Children's Hospital	5R01HD09134704	33,924	-
Child Health and Human Development Extramural Research	93.865	Nationwide Children's Hospital	5R01HD09597603	(8,534)	-
Child Health and Human Development Extramural Research	93.865	NewVentureIQ LLC	1R41HD09783301	3,612	-
Child Health and Human Development Extramural Research	93.865	Northwestern University	5K12HD07394510	52,477	-
Child Health and Human Development Extramural Research	93.865	Oklahoma State University	2R01HD07457911	9,818	-
Child Health and Human Development Extramural Research	93.865	Oregon Health & Science University	5U24HD10098202	16,827	-
Child Health and Human Development Extramural Research	93.865	Oregon Health & Science University	5U24HD10098203	24,900	-
Child Health and Human Development Extramural Research	93.865	Oregon Health & Science University	5U54HD10098202	21,826	-
Child Health and Human Development Extramural Research	93.865	Oregon Health & Science University	5U54HD10098203	168,241	-
Child Health and Human Development Extramural Research	93.865	Rector & Visitors Of The University Of Virginia	5R01HD07207107	114,745	-
Child Health and Human Development Extramural Research	93.865	Regents Of The University Of Colorado	5R01HD09799003	38,171	-
Child Health and Human Development Extramural Research	93.865	St. Louis College of Pharmacy	R33HD099748	76,707	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2022

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Child Health and Human Development Extramural Research	93.865	The Children's Hospital Of Philadelphia	5R01HD10152802	26,582	-
Child Health and Human Development Extramural Research	93.865	The Regents of the University of California	Unknown	1,928	-
Child Health and Human Development Extramural Research	93.865	Trustees Of Columbia University In The City Of New York	5R01HD09100305	12,580	-
Child Health and Human Development Extramural Research	93.865	University Of California Irvine	HD1023736	17,658	-
Child Health and Human Development Extramural Research	93.865	University Of California Los Angeles	5R01HD09247105	1,992	-
Child Health and Human Development Extramural Research	93.865	University Of California, San Francisco	5R01HD09241904	174,472	-
Child Health and Human Development Extramural Research	93.865	University Of Chicago	5R01HD09984702	17,864	-
Child Health and Human Development Extramural Research	93.865	University Of Maryland	5R03HD09939002	17,188	-
Child Health and Human Development Extramural Research	93.865	University Of North Carolina Chapel Hill	5R01HD05574115	389,852	-
Child Health and Human Development Extramural Research	93.865	University Of North Carolina Chapel Hill	5R01HD10390202	8,830	-
Child Health and Human Development Extramural Research	93.865	University Of Texas	7U01HD07738406	7,680	-
Child Health and Human Development Extramural Research	93.865	University Of Texas Health Science Center at Houston	1R01HD09766901	58,018	-
Child Health and Human Development Extramural Research	93.865	University Of Texas Southwestern	2P01HD08438706A1	2,411	-
Child Health and Human Development Extramural Research	93.865	University Of Texas Southwestern Medical Center	5P01HD08438704	94,610	-
Child Health and Human Development Extramural Research	93.865	University Of Washington	5R01HD10157802	73,073	-
Child Health and Human Development Extramural Research	93.865	Women and Infants Hospital of Rhode Island	1R01HD10585501A1	2,282	-
Child Health and Human Development Extramural Research	93.865	Yale University	1R01HD10632601	1,656	-
Aging Research	93.866			90,670,411	14,974,262
COVID-19-Aging Research	93.866			729,473	-
Aging Research	93.866	Active Life Scientific	1R22AG07103401	218,399	-
Aging Research	93.866	Baylor College of Medicine	5P01AG06660602	483,505	-
Aging Research	93.866	Baylor University	5R01AG06529002	126,575	-
Aging Research	93.866	Cancer and Aging Research Group	5R33AG05920604	3,083	-
Aging Research	93.866	Duke University	5R24AG05435506	17,101	-
Aging Research	93.866	Duke University	5R33AG07045502	33,100	-
Aging Research	93.866	Harvard School of Public Health	5R01AG06093503	80,759	-
Aging Research	93.866	Hebrew Rehabilitation Center	5R24AG05425905	4,575	-
Aging Research	93.866	Hebrew Rehabilitation Center	R33AG071744	14,100	-
Aging Research	93.866	Indiana University	5U01AG05719504	207,405	-
Aging Research	93.866	Johns Hopkins University	1RFAAG05986901	54,804	-
Aging Research	93.866	Mayo Clinic	1U19AG06970101	1,493,043	-
Aging Research	93.866	Mayo Clinic	5U19AG06391103	123,533	-
Aging Research	93.866	Mayo Clinic	WUB-284424/PO #68089509	283,817	-
Aging Research	93.866	Northern California Institute For Research And Education	U19AG024904	438,926	-
Aging Research	93.866	Northwestern University	3R01AG06857902S1	95,039	-
Aging Research	93.866	Northwestern University	5R01AG06912002	13,733	-
Aging Research	93.866	Northwestern University	5U2CA06042604	158,400	-
Aging Research	93.866	Ohio State University	R01AG056919	151,872	-
Aging Research	93.866	Oregon Research Institute	5R01AG02004824	14,425	-
Aging Research	93.866	Pennsylvania State University	5U2CAG06040804	82,164	-
Aging Research	93.866	Rector & Visitors Of The University Of Virginia	5R01AG06704802	115,270	-
Aging Research	93.866	Regenerative Research Foundation	1U1AG07246401	101,715	-
Aging Research	93.866	Regenerative Research Foundation	5R01AG05629305	171,641	-
Aging Research	93.866	Regents Of The University Of California	1RFAAG05900901	114,204	-
Aging Research	93.866	Regents Of The University Of Michigan	5R01AG06258203	2,757	-
Aging Research	93.866	Ridgeline Therapeutics LLC	1U44AG07410701	14,431	-
Aging Research	93.866	Rutgers The State University Of NJ	5R01AG05355605	869	-
Aging Research	93.866	Saint Louis University	1R21AG06552601A1	47,566	-
Aging Research	93.866	Saint Louis University	5R01AG05871404	9,741	-
Aging Research	93.866	St. Louis College of Pharmacy	9RFAAG06076906A1	39,509	-
Aging Research	93.866	The Board Of Trustees Of The Leland Stanford Junior University	5R37AG00881632	7,144	-
Aging Research	93.866	The Jackson Laboratory	1R01AG07401201	57,163	-
Aging Research	93.866	The Regents of the University of California	5U19AG01048326	5,353	-
Aging Research	93.866	Trustees Of Columbia University In The City Of New York	5U24UA05627005	78,619	-
Aging Research	93.866	Trustees Of Columbia University In The City Of New York	5U24UA5627004	1,988	-
Aging Research	93.866	Trustees Of The University Of Pennsylvania	1R01AG06857701	27,453	-
Aging Research	93.866	Trustees Of The University Of Pennsylvania	1R01AG06993601A1	61,589	-
Aging Research	93.866	Trustees Of The University Of Pennsylvania	5P01AG03186214	57,872	-
Aging Research	93.866	Trustees Of The University Of Pennsylvania	5P01AG03186215	2,572	-
Aging Research	93.866	Trustees Of The University Of Pennsylvania	5R01AG05443503	260,007	-
Aging Research	93.866	Tufts University	1R01AG071717-01A1	54,914	-
Aging Research	93.866	University Of Alabama Birmingham	1R01AG06839501A1	29,334	-
Aging Research	93.866	University Of California Los Angeles	5R01AG05436605	9,137	-
Aging Research	93.866	University Of California, San Francisco	5P30AG06242202	818	-
Aging Research	93.866	University Of California, San Francisco	5P30AG06242203	2,180	-
Aging Research	93.866	University Of California, San Francisco	5R01AG063879110	68,017	-
Aging Research	93.866	University Of California, San Francisco	5R01AG06235905	159,372	-
Aging Research	93.866	University Of Connecticut	5R01AG06886602	8,743	-
Aging Research	93.866	University Of Kentucky	5R01AG063865107	48,798	-
Aging Research	93.866	University Of Melbourne	5R01AG05867604	678,758	-
Aging Research	93.866	University Of Miami	5R01AG06461403	985,901	-
Aging Research	93.866	University Of Pittsburgh	1R01AG06487701A1	1,725,231	-
Aging Research	93.866	University Of Pittsburgh	1U19AG06805401	876,295	-
Aging Research	93.866	University Of Pittsburgh	3U01AG051406-05S3	108,552	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2022

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Aging Research	93.866	University of Pittsburgh	5R01AG06049904	418,583	-
Aging Research	93.866	University of Pittsburgh	5U01AG05140605	108,750	-
Aging Research	93.866	University of Pittsburgh	5U01AG05140605S4	644	-
Aging Research	93.866	University of Pittsburgh School of Medicine	1R01AG07326701	62,122	-
Aging Research	93.866	University of Rochester	5P01AG04720008	62,667	-
Aging Research	93.866	University of Rochester	5P01AG04720009	8,563	-
Aging Research	93.866	University of Southern California	136854271	71,331	-
Aging Research	93.866	University of Southern California	1R01AG05379801A1	11,462	-
Aging Research	93.866	University of Southern California	1R01AG06184801	5,730	-
Aging Research	93.866	University of Southern California	1R01AG06368901	15,352	-
Aging Research	93.866	University of Southern California	1R56AG05872601A1	43,747	-
Aging Research	93.866	University of Southern California	1R61AG06654301	65,841	-
Aging Research	93.866	University of Southern California	2U19AG02490413	36,837	-
Aging Research	93.866	University of Southern California	5R01AG05235005	150,020	-
Aging Research	93.866	University of Southern California	5R01AG05379803	15,770	-
Aging Research	93.866	University of Southern California	5R01AG05379804	22,246	-
Aging Research	93.866	University of Southern California	5U24AG05743704	9,189	-
Aging Research	93.866	University of Southern California	P01AG052350	27,241	-
Aging Research	93.866	University of Southern California	5R01AG04974905	131,819	-
Aging Research	93.866	University of Washington	1U24AG07212201	16,167	-
Aging Research	93.866	University of Washington	3U24AG07212201S1	8,662	-
Aging Research	93.866	University of Washington	5R01AG06375902	20,117	-
Aging Research	93.866	University of Washington	5U01AG01697621	157	-
Aging Research	93.866	University of Wisconsin	5R01AG07002802	291,874	-
Aging Research	93.866	University of Wisconsin	5R01AG07088302	54,978	-
Aging Research	93.866	Vanderbilt University Medical Center	1R01AG07343901	192,467	-
Aging Research	93.866	Vanderbilt University Medical Center	1U24AG074855-01	351,906	-
Aging Research	93.866	Yale University	5R01AG06591703	227,241	-
Aging Research	93.866	Yale University	5R33AG05892605	19,253	-
Aging Research	93.866	Yale University	5R61AG06982202	223,290	-
Vision Research	93.867			8,186,799	280,840
Vision Research	93.867	Cincinnati Children's Hospital Medical Center	1R01EY03275201	36,653	-
Vision Research	93.867	Johns Hopkins University	5UG1EY02809103	4,268	-
Vision Research	93.867	Legacy Emanuel Hospital & Health Center	5R34EY03142702	4,129	-
Vision Research	93.867	New York University	1U10EY02686901	2,223	-
Vision Research	93.867	Regents Of The University Of Michigan	5R01EY02664105	10,267	-
Vision Research	93.867	The Regents of the University of California	5R21EY03112502	(21,304)	-
Vision Research	93.867	University of Massachusetts Medical School	5R01EY02860203	89,101	-
Vision Research	93.867	University of Missouri System	1R21EY02910601A1	(915)	-
Vision Research	93.867	West Virginia University	1UG1EY03165401	3,572	-
Vision Research	93.867	West Virginia University	5UG1EY03165402	15,525	-
Medical Library Assistance	93.879			416,603	81,027
Medical Library Assistance	93.879	California Institute Of Technology	5U01LM01267203	1,370	-
Medical Library Assistance	93.879	University Of Arkansas	5R01LM01248204	32,934	-
Medical Library Assistance	93.879	University of California, San Francisco	1R01LM01377801	53,329	-
Global Health Research and Research Training	93.989			474,759	110,884
Global Health Research and Research Training	93.989	Centre for Infectious Disease Research in Zambia	1D71TW01183701	1,561	-
Global Health Research and Research Training	93.989	Centre for Infectious Disease Research in Zambia	1D71TW01183702	948	-
Global Health Research and Research Training	93.989	University Of Texas Health Science Center At San Antonio	9D43TW01179306A1	7,618	-
National Cancer Institute (NCI)	93.RD	Leidos Biomedical Research	20X012	41	-
National Cancer Institute (NCI)	93.RD	Leidos Biomedical Research	75N91019D00024-7591029Foo	197,684	-
COVID-19-National Cancer Institute (NCI)	93.RD	Leidos Biomedical Research	75N91019D00024	30,696	-
National Cancer Institute (NCI)	93.RD	Leidos Biomedical Research	HHSN261201500003I	511,748	-
National Cancer Institute (NCI)	93.RD	Medical Science & Computing	75N98020D00086/75N98020Fo	6,106	-
National Cancer Institute (NCI)	93.RD	Medical Science & Computing	75N98020F00014	3,776	-
COVID-19-National Cancer Institute (NCI)	93.RD	NRG Oncology Foundation	Unknown	3,671	(1,071)
National Heart, Lung and Blood Institute (NHLBI)	93.RD	Westat	10T2HL16161401	652,471	-
National Heart, Lung and Blood Institute (NHLBI)	93.RD			15,924	-
National Heart, Lung and Blood Institute (NHLBI)	93.RD			83,561	-
National Heart, Lung and Blood Institute (NHLBI)	93.RD	Johns Hopkins University	A345896	24,587	-
National Heart, Lung and Blood Institute (NHLBI)	93.RD	Emmes Company	HHSN26182011400002I	17,567	-
National Heart, Lung and Blood Institute (NHLBI)	93.RD	I3 Healthcare	75N92021P00049	20,275	-
COVID-19-National Heart, Lung and Blood Institute (NHLBI)	93.RD	I3 Healthcare	75N92021D0008	257,411	-
COVID-19-National Heart, Lung and Blood Institute (NHLBI)	93.RD	New York University	OT2HL156812	275,847	-
National Heart, Lung and Blood Institute (NHLBI)	93.RD	University of Michigan	5000019445	155,855	-
National Heart, Lung and Blood Institute (NHLBI)	93.RD	University of Michigan	5500021866	189,553	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD			1,717,890	326,889
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Ichan School of Medicine at Mt. Sinai	0258-A705-4609	93,061	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Ichan School of Medicine at Mt. Sinai	75N93019C0005	1,119,718	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Ichan School of Medicine at Mt. Sinai	HHSN272201400008C	328,183	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Infectious Disease Research Institute	HHSN272201400041C	7,118	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Northwestern University	HHSN272201700060C	602,994	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	Rutgers University	HHSN271201800023I	405,933	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	St. Jude Children's Research Institute	75N93021C00016	450,636	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2022

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	St. Jude Children's Research Institute	HHSN272201400006C	367,998	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	University of Alabama, Birmingham	HHSN272201600018C	5,806	-
National Institute of Allergy and Infectious Diseases (NIAID)	93.RD	University of Montana	HHSN272201400050C	108,756	-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	93.RD			99,900	-
National Institutes of Health (NIH)	93.RD	Adjuvance Technologies	HHSN272201700066C	189,662	-
National Institutes of Health (NIH)	93.RD	Duke University	HHSN275201000003I	89,378	-
National Institutes of Health (NIH)	93.RD	Duke University	R01AI12504507	62,440	-
National Institutes of Health (NIH)	93.RD	Ecog-Acrin Medical Research Foundation	PDS137629	11,411	-
National Institutes of Health (NIH)	93.RD	Ichan School of Medicine at Mt. Sinai	75N93021C00014	166,169	-
National Institutes of Health (NIH)	93.RD	Radiologics	75N91020C00025	47,442	-
COVID19-National Institutes of Health (NIH)	93.RD	RTI International	10THL15681201	106,028	-
National Institutes of Health (NIH)	93.RD	University of Wisconsin	Unknown	29,776	-
National Institutes of Health (NIH)	93.RD	University of Wisconsin		12,646	-
National Institutes of Health (NIH)	93.RD	Vivent	RWB_VIVENTTOWU_FY20-21	180,623	-
National Institutes of Health (NIH)	93.RD	Westat	HHSN261201600007I	19,401	-
National Institutes of Health (NIH)	93.RD	Yale University		(21,139)	-
Office of Population Affairs					
Family Planning Services	93.217	Missouri Family Health Council	FPHPA006455	179,092	-
Substance Abuse and Mental Health Services Administration					
Projects of Regional and National Significance	93.243			91,823	-
Substance Abuse and Mental Health Services Administration	93.RD	University of Missouri, St. Louis	00074569-1	2,017	-
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES				629,488,092	63,728,194
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION					
National Aeronautics and Space Administration					
Science	43.001			7,283,899	924,089
Science	43.001	California Institute of Technology	80NSSC18K0223	119,758	-
Science	43.001	California Institute of Technology	80NSSC20K0540	23,853	-
Science	43.001	Jet Propulsion Laboratory	1628233	36,148	-
Science	43.001	Jet Propulsion Laboratory	1639750	66,319	-
Science	43.001	Jet Propulsion Laboratory	1649883	68,562	-
Science	43.001	Jet Propulsion Laboratory	1675527	13,297	-
Science	43.001	Princeton University	80NSSC21K1957	14,409	-
Science	43.001	Rensselaer Polytechnic Institute	80NSSC19M0069	45,023	-
Science	43.001	Smithsonian Astrophysical Observatory	GO0-21046A	15,083	-
Science	43.001	Smithsonian Astrophysical Observatory	GO021103A	4,827	-
Science	43.001	Smithsonian Astrophysical Observatory	GO122033B	5,137	-
Science	43.001	Smithsonian Astrophysical Observatory	GO122091X	18,899	-
Science	43.001	Smithsonian Astrophysical Observatory	GO920034X	21,353	-
Science	43.001	Smithsonian Astrophysical Observatory	NAS8-03060	27,646	-
Science	43.001	Smithsonian Astrophysical Observatory	TMI1-22003X	14,841	-
Science	43.001	University of Chicago	80NSSC21M0116	78,126	-
Science	43.001	University of Hawaii	80NSSC20K0361	9,960	-
Science	43.001	University of New Mexico	80NSSC19K0958	126,309	-
Space Operations	43.007			189,034	-
Education	43.008	Missouri University of Science and Technology	80NSSC20M0100	109,062	-
Space Technology	43.012			455,487	90,028
NASA	43.RD	Arizona State University	NNG07EK00C	145,010	-
NASA	43.RD	Jet Propulsion Laboratory	1549716	211,022	-
NASA	43.RD	Jet Propulsion Laboratory	1658021	16,899	-
NASA	43.RD	Jet Propulsion Laboratory	NM0710630	40,146	-
NASA	43.RD	Jet Propulsion Laboratory	NM0710805	97,847	-
NASA	43.RD	Southwest Research Institute	NASW02008SWRI 1505310	52,236	-
NASA	43.RD	Southwest Research Institute	NNI12AA01C	7,937	-
NASA	43.RD	University of Texas Austin	NNM16AA26C	7,540	-
TOTAL NATIONAL AERONAUTICS AND SPACE ADMINISTRATION				9,325,669	1,014,117
NATIONAL SCIENCE FOUNDATION					
National Science Foundation					
Engineering Grants	47.041			4,240,079	446,319
COVID19-Engineering Grants	47.041			27,203	-
Engineering Grants	47.041	University of Central Florida	1908167	91,947	-
Engineering Grants	47.041	University of Illinois	1900277	22,410	-
Engineering Grants	47.041	University of Pennsylvania	CMMI1548571	748,349	-
Mathematic and Physical Sciences	47.049			3,415,575	29,267
Mathematic and Physical Sciences	47.049	Barnard College	1828168	50,662	-
Mathematic and Physical Sciences	47.049	Harvard University	2127882	129,227	-
Mathematic and Physical Sciences	47.049	University of Minnesota	CHE1906135	158,862	-
Geosciences	47.050			1,393,101	10,137
Geosciences	47.050	Cornell University	1654568	15,847	-
Computer and Information Science and Engineering	47.070			3,128,850	58,440
Computer and Information Science and Engineering	47.070	Colorado School of Mines	2118201	78,999	-
Computer and Information Science and Engineering	47.070	George Mason University	E2055321	40,636	-
Computer and Information Science and Engineering	47.070	Georgia Institute of Technology	IIS2027689	14,368	-

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2022

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Computer and Information Science and Engineering	47.070	University of California, Berkely	NSF1640899	119,765	40,184
Computer and Information Science and Engineering	47.070	University of Illinois, Urbana-Champaign	2103680	37,896	-
Computer and Information Science and Engineering	47.070	University of Utah	1564287	(11,428)	-
Computer and Information Science and Engineering	47.070	University of Utah	1622741	36,608	-
Computer and Information Science and Engineering	47.070	University of Utah	2002158	259,250	-
Computer and Information Science and Engineering	47.070	University of Utah	CNS182688	30,716	-
Computer and Information Science and Engineering	47.070	University of Utah	CNS1827940	88,065	-
Computer and Information Science and Engineering	47.070	Virginia Polytech Institute	CNS-1837519	67,110	-
Computer and Information Science and Engineering	47.070	West Virginia University	IIS-2114644	9,418	-
Biological Sciences	47.074	American University	1948181	3,385,840	352,338
Biological Sciences	47.074	Baylor College of Medicine	2131806	49,168	-
Biological Sciences	47.074	Baylor College of Medicine	DBI2021795	10,352	-
Biological Sciences	47.074	University of Wisconsin, Madison	1818040	277,647	-
Biological Sciences	47.074	University of Wisconsin, Madison	1840687	24,756	-
Social, Behavioral, and Economic Sciences	47.075			123,989	-
Social, Behavioral, and Economic Sciences	47.075	Boston University	SES2120115	1,110,790	22,792
Social, Behavioral, and Economic Sciences	47.075	Georgia State University	1740201	27,179	-
Education and Human Resources	47.076			13,688	-
Education and Human Resources	47.076	Harris-Stowe State University	1619639	1,669,163	41,620
Education and Human Resources	47.076	Jackson State University	2000135	50,718	-
Education and Human Resources	47.076	University of Alabama	1915544	25,624	-
Polar Programs	47.078			39,841	-
Office of International Science and Engineering	47.079			31,090	-
Office of International Science and Engineering	47.079	CFDF Global	OISE9531011	155,815	-
COVID19-Office of Integrative Activities	47.083	University of Wisconsin	OISE20665901	3,450	-
TOTAL NATIONAL SCIENCE FOUNDATION				29,265	-
				21,221,890	1,001,097
AGENCY FOR INTERNATIONAL DEVELOPMENT					
Agency for International Development					
Agency for International Development Foreign Assistance for Programs Overseas	98.001	Michigan State University	7200AA18LE0003	(65)	(65)
Agency for International Development Foreign Assistance for Programs Overseas	98.001	Mississippi State University	7200AA18CA00030	104,408	-
Agency for International Development Foreign Assistance for Programs Overseas	98.001	National Academy of Sciences	AID263A1500002	52,281	-
Agency for International Development Foreign Assistance for Programs Overseas	98.001	Purdue University	AID7200AA18CA00009	19,478	-
Agency for International Development Foreign Assistance for Programs Overseas	98.001	Task Force for Global Health	AID0AAG1400008	2,766	-
Agency for International Development Foreign Assistance for Programs Overseas	98.001	University of Georgia	7200AA18CA00003	228,301	47,410
Agency for International Development Foreign Assistance for Programs Overseas	98.001	Washington State University	7200AA21CA00033/L6NFUM28LQM5	230,901	-
Agency for International Development	98.RD	Catholic Relief Services	720BHA21RFA00002	26,686	-
Agency for International Development	98.RD	Mississippi State University	19390031245502E	36,018	-
Agency for International Development	98.RD	Transcultural Psychosocial Organization	AID-OAA-A-17-00002	30,068	-
Agency for International Development	98.RD	University of Mississippi	7200AA18CA00030	54,246	-
DEPARTMENT OF AGRICULTURE					
National Institute of Food and Agriculture					
Biotechnology Risk Assessment Research	10.219			160,458	-
Agriculture and Food Research Initiative (AFRI)	10.310			257,371	-
Agricultural Research Basic and Applied Research	10.001	CRDF Global	DAA320669471	29,230	-
Agriculture and Food Research Initiative (AFRI)	10.310	Washington State University	141192 SPC004397	29,960	-
Agriculture and Food Research Initiative (AFRI)	10.310	University Of Hawaii	2020-67022-31146	75,914	-
DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT					
Department of Housing and Urban Development					
Office of Healthy Homes and Lead Hazard Control	14.906			59,476	3,000
DEPARTMENT OF THE INTERIOR					
U.S. Geological Survey					
Assistance to State Water Resources Research Institutes	15.805	University of Missouri	G16AP00066	5,725	-
DEPARTMENT OF JUSTICE					
Crime Victim Assistance/Discretionary Grants	16.582			62,953	-
DEPARTMENT OF STATE					
Public Diplomacy Programs	19.040			22,359	-
Overseas Refugee Assistance Programs for Strategic Global Priorities	19.522			284,685	-
DEPARTMENT OF TRANSPORTATION					
Federal Highway Administration					
National Highway Traffic Safety Administration	20.RD	Wake Forest University	DTNH2217D00070	39,242	-
DEPARTMENT OF VETERANS AFFAIRS					
Department of Veterans Affairs	64.RD			186,155	-
ENVIRONMENTAL PROTECTION AGENCY					
Office of Research and Development	66.RD			19,999	-
Environmental Protection Agency	66.509	NanoSonic	68HERC20R0111	380,422	-
Science to Achieve Results (STAR) Research Program					
NATIONAL ENDOWMENT FOR THE HUMANITIES					
Promotion of the Arts Grants to Organizations and Individuals	45.024			70,445	-
Promotion of the Humanities - Fellowships and Stipends	45.160			30,523	-
Promotion of the Humanities Federal/State Partnership	45.129	Missouri Humanities Council	ZSO-283147-21	40,829	-
Total Research & Development Cluster				696,114,613	69,092,653

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2022

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Other Sponsored Programs					
DEPARTMENT OF DEFENSE					
U.S. Army Medical Command					
Military Medical Research and Development	12.U01	University of Pittsburgh School of Medicine	W81XWJ16D0024W81XWH18F04	74,817	-
TOTAL DEPARTMENT OF DEFENSE				<u>74,817</u>	<u>-</u>
DEPARTMENT OF HEALTH AND HUMAN SERVICES					
Administration for Community Living					
Empowering Older Adults and Adults with Disabilities through Chronic Disease Self-Management Education Programs	93.734	University of Missouri System	C00062994-3	13,964	-
Alzheimer's Initiative	93.763	Memory Home Care Solutions	90ADPI00210100	817	-
Centers for Disease Control					
Autism and Other Developmental Disabilities					
	93.998			370,616	-
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	University of Texas Health Science Center	5NU27DD00115505	10,344	-
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	University of Texas Health Science Center	NU27DD000020-01-00	10,934	-
TOTAL BLOOD DISORDER PROGRAM				<u>21,278</u>	<u>-</u>
Centers for Disease Control and Prevention	93.U01			36,822	-
Centers for Disease Control and Prevention	93.U02			110,380	-
Centers for Disease Control and Prevention	93.U03			490,039	-
Centers for Disease Control and Prevention	93.U07	Summit (Oxford) Limited	1009191	7,056	-
Colorectal Cancer Screening Program	93.800	University of Missouri	5NU58DP0067650300	19,763	-
HIV Prevention Activities_Health Department Based	93.940	Missouri Department of Health and Human Services	DH200047810	113,391	-
HIV Prevention Activities_Health Department Based	93.940	City of St. Louis Department of Health	11107110010	33,914	-
HIV Prevention Activities_Health Department Based	93.940	City of St. Louis Department of Health	11667114011	77,929	-
HIV Prevention Activities_Health Department Based	93.940	City of St. Louis Department of Health	1166-7114720	75,067	-
HIV Prevention Activities_Health Department Based	93.940	City of St. Louis Department of Health	20-22	7,122	-
TOTAL HIV PREVENTION ACTIVITIES_HEALTH DEPARTMENT BASED				<u>307,423</u>	<u>-</u>
Department of Health and Human Services					
HIV Prevention Activities Non-Governmental Organization Based	93.939	Vivent Health	1NU62PS924648-01-00	51,065	-
Assistance Programs for Chronic Disease Prevention and Control	93.945	Missouri Department Of Health & Senior Services	DH200048448	33,440	-
Food and Drug Administration					
Food and Drug Administration	93.U09			186,181	-
Food and Drug Administration	93.U10			30,556	-
Health Resources and Services Administration					
Health Resources and Services Administration	93.U14	St. Clair County	Unknown	71,663	-
Trans-NIH Research Support	93.110	University of Texas Health Science Center At San Antonio	5H30MC240510700	22,006	-
Emergency Medical Services for Children	93.127	Cincinnati Children's Hospital Medical Center	5U03MC22684-11-00	108,916	-
Emergency Medical Services for Children	93.127	Cincinnati Children's Hospital Medical Center	6U03MC226841001	24,799	-
TOTAL EMERGENCY MEDICAL SERVICES FOR CHILDREN				<u>133,715</u>	<u>-</u>
Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153			1,470,871	84,307
Sickle Cell Treatment Demonstration Program	93.365			781,187	426,504
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	22-56	2,735	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	21-82	74,993	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	21-83	21,127	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	21-84	538,486	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	Unknown	612,739	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	2H89HA000332400	48,948	-
HIV Emergency Relief Project Grants	93.914	City of St. Louis Department of Health	2H89HA000332800	39,920	-
TOTAL HIV EMERGENCY RELIEF PROJECT GRANTS				<u>1,338,948</u>	<u>-</u>
HIV Care Formula Grants	93.917	Missouri Department of Health and Senior Services	X07HA00030	380,401	72,079
HIV Care Formula Grants	93.917	Missouri Department of Health and Senior Services	DH200048389	385,837	-
TOTAL HIV CARE FORMULA GRANTS				<u>766,238</u>	<u>72,079</u>
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918			485,148	45,805
Special Projects of National Significance	93.928			314,931	35,151
Office of the Secretary of Health and Human Services					
COVID19-Biomedical Advanced Research and Development Authority (BARDA)	93.U16	Duke University	HHSO1002014000021	798,738	

The accompanying notes are an integral part of this schedule.

Washington University

Schedule of Expenditures of Federal Awards

For the Year Ended June 30, 2022

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Substance Abuse and Mental Health Services Administration Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243			303,347	-
State Targeted Response to the Opioid Crisis Grants	93.788	University of Missouri, St. Louis	AOC21380034	197,822	-
Substance Abuse and Mental Health Services Administration	93.U17	St. Louis County Department of Health	HE20200169	2,902	-
Substance Abuse and Mental Health Services Administration	93.U18	Vision for Children at Risk	VCRSTLPL	116,239	-
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES				8,483,155	663,846
OTHER FEDERAL PROGRAMS					
DEPARTMENT OF ENERGY					
DEPARTMENT OF Energy	81.U01			25,117	-
DEPARTMENT OF HOMELAND SECURITY					
Countering Weapons of Mass Destruction	97.077	City of St. Louis	19DNFRV00010201	99,417	-
DEPARTMENT OF JUSTICE					
Office of Juvenile Justice and Delinquency Prevention Community-Based Violence Prevention Program	16.123	United Way of Greater St. Louis	2017MUMUK006	4,000	-
Second Chance Act Reentry Initiative	16.812	Soulfisher Minsitry	2018CYBX0018	17,478	-
DEPARTMENT OF THE TREASURY					
Internal Revenue Service					
Low Income Taxpayer Clinics	21.008			90,577	-
NATIONAL ARCHIVES AND RECORDS ADMINISTRATION					
National Archives and Records Administration National Archives and Records Administration	89.U01	National Film Preservation Foundation	FED18022	203	-
	89.003			1,887	-
NATIONAL ENDOWMENT FOR THE ARTS Promotion of the Arts Grants to Organizations and Individuals	45.024			(781)	-
NATIONAL ENDOWMENT FOR THE HUMANITIES					
Promotion of the Humanities Division of Preservation and Access	45.149			39,620	3,116
Total Other Sponsored Programs from Other Federal Agencies				277,518	3,116
Total Other Sponsored Programs				8,835,490	666,962
Student Financial Assitance Cluster					
DEPARTMENT OF EDUCATION					
Federal Supplemental Educational Opportunity Grant	84.007			1,402,576	-
Federal Work-Study Program	84.033			1,475,576	-
Federal Pell Grant Program	84.063			-	-
Teacher Education Assistance for College and Higher Education Grants	84.379			-	-
Education Stabilization Fund	84.425			578	-
Federal Direct Student Loans					
Outstanding Loans as of July 1, 2021	84.268			-	-
New Loans Issued during 2022	84.268			99,472,564	-
Administrative Cost Allowance	84.268			-	-
Federal Perkins Loans					
Outstanding Loans as of July 1, 2021	84.038			10,482,949	-
New Loans Issued during 2022	84.038			-	-
Administrative Cost Allowance	84.038			-	-
DEPARTMENT OF HEALTH AND HUMAN SERVICES					
Health Professions Student Loans including Primary Care Loans/Loans for Disadvantaged Students					
Outstanding Loans as of July 1, 2021	93.342			-	-
New Loans Issued during 2022	93.342			-	-
Administrative Cost Allowance	93.342			-	-
Total Student Financial Assistance Cluster				112,834,243	-
DEPARTMENT OF EDUCATION					
COVID19-Higher Education Emergency Relief Fund - Student Aid Portion	84.425E			6,941,312	-
COVID19-Higher Education Emergency Relief Fund - Institutional Portion	84.425F			1,476,875	-
DEPARTMENT OF HEALTH AND HUMAN SERVICES					
COVID19-Claims Reimbursement for the Uninsured Program	93.461			-	-
COVID19-Provider Relief Fund	93.498			-	-
Highway Safety Cluster					
DEPARTMENT OF TRANSPORTATION					
Police Traffic Services	20.600	Missouri Dept of Transportation	20DL02001	133,072	-
Total Highway Safety Cluster				133,072	-
TRIO Cluster					
DEPARTMENT OF EDUCATION					
TRIO - Student Support Services	84.042			254,579	-

The accompanying notes are an integral part of this schedule.

Washington University
Schedule of Expenditures of Federal Awards
For the Year Ended June 30, 2022

Cluster Title/Federal Grantor/Program Title	Assistance Listing Number	Pass Through Entity	Pass-through Entity Identification Number	Total Expenditures	Passed to Sub-Recipients
Medicaid Cluster DEPARTMENT OF HEALTH AND HUMAN SERVICES Medical Assistance Program	93.778	Missouri Department of Health and Senior Services	ER100160099	236,083	-
Total Federal Award Expenditures				<u>\$ 826,826,267</u>	<u>\$ 69,759,615</u>

The accompanying notes are an integral part of this schedule.

Washington University
Notes to Schedule of Expenditures of Federal Awards
For the Year Ended June 30, 2022

1. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the “Schedule”) summarizes the expenditures of Washington University (the “university”) under programs of the Federal Government for the year ended June 30, 2022. Expenditures of direct awards to the university are reported in total by program. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulation Part 200, *Uniform Administrative Requirements, Cost Principals, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in the preparation of, the basic financial statements. The university includes the amounts in the Schedule in the net assets without donor restrictions of the university’s Consolidated Statement of Activities for the year ended June 30, 2022.

The Schedule is prepared on the accrual basis of accounting. Assistance Listing and pass-through numbers are provided when available. Negative amounts presented as expenditures represent subsequent period adjustments, transfers, or vendor credits. Expenditures are recognized following the cost accounting principles contained in the Uniform Guidance wherein certain types of expenditures are not allowable or are limited to reimbursement. Moreover, expenditures include a portion of costs associated with general university activities which are allocated to awards under negotiated formulas commonly referred to as facilities and administrative cost rates.

Federal Awards

For purposes of the Schedule, federal awards include all grants, contracts and similar agreements entered into directly by the university with agencies and departments of the Federal Government and all awards received as a subrecipient from nonfederal organizations pursuant to federal grants, contracts and similar agreements.

2. Facilities and Administrative Costs

The university recovers facilities and administrative costs under federal financial assistance programs using predetermined rates ranging from 26.0% to 57.5%. The university does not use the 10% de minimis cost rate but instead has negotiated the rates above with the Department of Health and Human Services through June 30, 2022.

3. Federal Student Loan Programs

The following schedule includes the SFA loan balances outstanding as of June 30, 2022:

Student Financial Aid	Federal Assistance Listing Number	Outstanding Balances
U.S. Department of Education		
Federal Perkins Loan Program	84.038	10,482,949

Report on Compliance and on Internal Controls



Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

To the Board of Trustees of Washington University

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Washington University and its subsidiaries (the "University"), which comprise the consolidated statement of financial position as of June 30, 2022, and the related consolidated statements of activities and of cash flows for the year then ended, including the related notes (collectively referred to as the consolidated financial statements), and have issued our report thereon dated October 7, 2022.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the University's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

PricewaterhouseCoopers LLP

St. Louis, Missouri
October 7, 2022



Report of Independent Auditors on Compliance for Each Major Program and on Internal Control over Compliance Required by Uniform Guidance

To the Board of Trustees of Washington University

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Washington University's (the "University") compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the University's major federal programs for the year ended June 30, 2022. The University's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the University complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2022.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (US GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the University's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the University's federal programs.

Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the University's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance



with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the University's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the University's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the University's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Other Matters

The results of our auditing procedures disclosed an instance of noncompliance, which is required to be reported in accordance with the Uniform Guidance and which is described in the accompanying schedule of findings and questioned costs as item 2022-001. Our opinion on each major federal program is not modified with respect to this matter.

Government Auditing Standards requires the auditor to perform limited procedures on the University's response to the noncompliance findings identified in our audit described in the accompanying schedule of findings and questioned costs and corrective action plan. The University's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.



Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

PricewaterhouseCoopers LLP

St. Louis, Missouri
March 3, 2023

Schedule of Findings and Questioned Costs

Washington University
EIN# 43-0653611
Schedule of Findings and Questioned Costs
For the Year Ended June 30, 2022

Part I - Summary of Auditor's Results

Financial Statements

Type of auditor's report issued: Unmodified

Internal control over financial reporting:

Material weakness (es) identified? Yes No

Significant deficiency (ies) identified not considered to be material weaknesses? Yes None reported

Noncompliance material to financial statements noted? Yes No

Federal Awards

Type of auditor's report issued on compliance for major programs: Unmodified

Internal control over major programs:

Material weakness (es) identified? Yes No

Significant deficiency (ies) identified not considered to be material weaknesses? Yes None reported

Any audit findings disclosed that are required to be reported in accordance with Uniform Guidance Section 200.516(a)? Yes No

Identification of Major Programs:

<u>Assistance Listing Number(s)</u>	<u>Name of Federal Program or Cluster</u>
Various	Research and Development Cluster
84.425E/F	COVID 19 Higher Education Emergency Relief Fund – Student/ Institutional Portion
93.U16	COVID 19 Biomedical Advanced Research and Development Authority (BARDA)

Dollar threshold used to distinguish between Type A and Type B programs: \$3,000,000

Auditee qualified as low-risk auditee? Yes No

Washington University
EIN# 43-0653611
Schedule of Findings and Questioned Costs
For the Year Ended June 30, 2022

Part II – Financial Statement Findings

There are no financial statement findings to report.

Part III – Federal Award Findings and Questioned Cost

Finding 2022-001 Allowable costs/cost principles

Grantor:	Various
Program:	Research and Development Cluster
Assistance Listing#:	Various
Award Title:	Various
Award Year:	07/1/2021 – 06/30/2022
Award Number:	Various
Pass-through Number:	Various

Criteria

2 CFR part 200 and 2 CFR part 200, Appendix III which requires entities to ensure that the negotiated (or submitted) indirect cost rates are correctly applied to the appropriate distribution base to arrive at allowable indirect costs that may be charged to a sponsored award.

Condition

During fiscal year 2022, management identified several instances where indirect costs on subawards were not appropriately charged to the sponsor. The error totaled \$3,497,981, of which \$3,475,522 is related to the Research and Development Cluster and the remaining \$22,458 is related to other federal programs.

Cause

The University transitioned to a new ERP system at the beginning of the fiscal year. Certain subaward parameters that prevented charging sponsored awards in excess of allowable indirect costs amounts were not consistently established in the new ERP system.

Effect

Indirect costs in excess of the allowable amounts were charged to certain federal awards.

Questioned Costs

The total questioned costs associated with this finding are \$3,497,981. As of June 30, 2022, \$98 had been corrected in the ERP system and the associated funds were remitted back to the sponsor. The remaining items totaling \$3,497,882 have been corrected during fiscal year 2023 along with any remaining funds requiring remittance to the sponsor.

Recommendation

Management should perform a review of all sponsored programs involving subawards to ensure the indirect cost rate along with any limitations associated with charging indirect costs are completely and accurately captured in the ERP system. Any errors identified should be promptly corrected and refunds should be remitted to the sponsor for instances where the sponsor was over charged for indirect costs.

Management's View and Corrective Action Plan

Please refer to management's corrective action plan for management's response and corrective action related to this finding.

Corrective Action Plan



Finding 2022 – 001: Allowable Costs/Cost Principles

Management concurs with this finding and we have implemented the following correcting actions:

- In Workday, the Basis Limit field is the key mechanism that will determine whether a subaward charges the appropriate amount of overhead. We have reviewed the current grants that have out-going subawards and added/updated the Basis Limit as applicable.
- The staff in Sponsored Projects Accounting that create new accounts have received additional training on how/when to load a Basis Limit for out-going subawards.
- New reports have been created which identify that Basis Limits entered are complete and appropriate and these are reviewed on a monthly basis.
- As a result of the 2022R2 Workday Feature Release (9/22), Management has added a custom validation that will require a Basis Limit when an out-going subaward is included on a grant.

Completion Date: January 2023

University Contact and Responsible Party: Joseph M. Gindhart, (314) 935-7089

Summary Schedule of Prior Audit Findings and Status

Washington University
Summary Schedule of Prior Audit Findings and Status
For the Year Ended June 30, 2022

Part IV – Federal Award Findings

There were no federal award findings and questioned costs in prior years that require an update in this report.